NCT ID,Title,Phase,Drug Names,Modality,Target,Indication,Status,Sponsor,Start Date,Primary Completion,Milestone,Probability,Phase_Num,Modality_Code,ML_Prediction,Phase Weight
NCT03902665,Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75,PHASE2,Up-front allogeneic hematopoietic stem cell transplantation (HSCT),Other,Unknown,Leukemia,COMPLETED,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,2019-03-15,2024-03-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02998567,Combination Study of Guadecitabine/ASTX727 and Pembrolizumab,PHASE1,"Guadecitabine, Pembrolizumab, ASTX727",Other,Unknown,Solid Tumor,RECRUITING,Royal Marsden NHS Foundation Trust,2017-01-26,2026-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05400265,"Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor",PHASE1,"HLX26, HLX10",Other,Unknown,Solid Tumor,COMPLETED,Shanghai Henlius Biotech,2022-07-26,2023-08-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03013712,A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,UNKNOWN,First Affiliated Hospital of Chengdu Medical College,2017-01,2018-12,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT03420430,Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care,,,CAR-T,Unknown,Leukemia,NO_LONGER_AVAILABLE,Genelux Corporation,,,Unknown,0.1,,2,0.07698823195888042,1
NCT03226119,MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study,PHASE4,,Other,Unknown,Lymphoma,COMPLETED,"MP Biomedicals, LLC",2018-01-15,2018-07-10,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT00243100,Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors,PHASE1,"vorinostat, gemcitabine hydrochloride",Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2005-11,2011-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04345900,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2,PHASE2,"Plinabulin, Pegfilgrastim",Other,Unknown,Solid Tumor,COMPLETED,BeyondSpring Pharmaceuticals Inc.,2017-04-05,2018-03-20,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00931138,"Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2",PHASE3,"chemotherapy (Aracytine + Daunorubicin), chemotherapy (Aracytine + Daunorubicin), chemotherapy (Aracytine + Daunorubicin)",Other,Unknown,Leukemia,COMPLETED,Acute Leukemia French Association,1999-12,,Unknown,0.6,3.0,3,0.600000000000001,5
NCT01226407,Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile,PHASE1,CG200745,Other,Unknown,Other,UNKNOWN,"CrystalGenomics, Inc.",2010-09,2013-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00470405,Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma,PHASE1,"oxaliplatin, pemetrexed disodium",Other,Unknown,Lymphoma,COMPLETED,Vanderbilt-Ingram Cancer Center,2004-05,2007-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05787951,Frequency and Risk Factors of Acute Myeloid Leukemia,,,Other,Unknown,Leukemia,UNKNOWN,Assiut University,2023-05-01,2025-05-01,Long-term,0.1,,3,0.07471722255609645,1
NCT00739453,A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®),PHASE1,"OSI-906, erlotinib",Other,Unknown,Solid Tumor,COMPLETED,Astellas Pharma Inc,2008-10-23,2012-03-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05378737,"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection",PHASE1,BAT8006 for Injection,Other,Unknown,Solid Tumor,COMPLETED,Bio-Thera Solutions,2022-07-06,2025-12-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05174637,A Study of FDA018-ADC in Patients With Advanced Solid Tumors,PHASE1,FDA018-ADC,ADC,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",2021-10-22,2029-12,Long-term,0.1,1.0,0,0.17008722943722948,1
NCT06292845,Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents,NA,Topical application of a fluorescent imaging agent,Other,Unknown,Solid Tumor,RECRUITING,Erasmus Medical Center,2024-01-16,2027-12-01,Long-term,0.05,,3,0.07471722255609645,1
NCT06152172,CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101,PHASE1,"KYV-101, Cyclophosphamide, Fludarabine",CAR-T,Unknown,Other,ACTIVE_NOT_RECRUITING,David Porter,2024-08-05,2026-02,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06552572,Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy,PHASE2,Glofitamab,Other,CD19,Lymphoma,ACTIVE_NOT_RECRUITING,Samsung Medical Center,2024-11-26,2026-06-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01949545,Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment,PHASE1,Carfilzomib,CAR-T,Unknown,Solid Tumor,COMPLETED,Amgen,2013-10,2015-08,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT01757639,Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia,PHASE1,,Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2012-12-14,2016-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,PHASE1,"Carboplatin, Cisplatin, Palbociclib",CAR-T,Unknown,Solid Tumor,COMPLETED,Emory University,2016-10-24,2021-10-15,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00807677,A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies,PHASE1,TAK-901,Other,Unknown,Lymphoma,COMPLETED,"Millennium Pharmaceuticals, Inc.",2009-03,2012-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06113575,Practical Application of Accelerated iTBS for MDD,NA,,Other,Unknown,Other,COMPLETED,Sonder Behavioral Health and Wellness,2022-11-23,2023-07-28,Long-term,0.05,,3,0.07471722255609645,1
NCT00208975,"Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab",PHASE2,"Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF",Other,Unknown,Lymphoma,TERMINATED,Emory University,2002-07,2009-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05747157,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research,EARLY_PHASE1,Metabolically Armed CD19 CAR-T cells,CAR-T,CD19,Leukemia,UNKNOWN,Anhui Provincial Hospital,2023-02-15,2025-02-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03441555,A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia,PHASE1,"Venetoclax, Alvocidib",Other,Unknown,Leukemia,COMPLETED,AbbVie,2018-05-30,2021-01-25,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03662815,Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor,PHASE1,,Other,Unknown,Solid Tumor,UNKNOWN,Sir Run Run Shaw Hospital,2018-02-07,2021-05-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00242515,T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),"PHASE1, PHASE2",,Other,Unknown,Leukemia,UNKNOWN,"National University Hospital, Singapore",2005-03,,Unknown,0.3,1.0,3,0.15123598159865156,3
NCT03221335,EUS-guided RFA for Solid Abdominal Neoplasms,NA,,Other,Unknown,Other,UNKNOWN,Chinese University of Hong Kong,2016-05,2024-04,Long-term,0.05,,3,0.07471722255609645,1
NCT01501708,Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection,PHASE2,Caspofugin based combination therapy,Other,Unknown,Leukemia,UNKNOWN,Shanghai Jiao Tong University School of Medicine,2011-12,2017-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02398240,Brentuximab for Newly Diagnosed Hodgkin Disease,PHASE2,"Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab",Other,Unknown,Lymphoma,COMPLETED,Mitchell Cairo,2015-05,2022-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03268889,"Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)",NA,Chidamide,Other,Unknown,Lymphoma,UNKNOWN,The First Affiliated Hospital of Soochow University,2017-06-15,2020-06-15,Long-term,0.05,,3,0.07471722255609645,1
NCT02502968,BL-8040 Addition to Consolidation Therapy in AML Patients,PHASE2,"Cytarabine, BL-8040, Placebo (for BL-8040)",Other,Unknown,Leukemia,UNKNOWN,Dr. Petra Tschanter,2015-09,2018-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,PHASE3,levofloxacin,Other,Unknown,Lymphoma,COMPLETED,Cancer Research Campaign Clinical Trials Centre,1999-08,,Unknown,0.6,3.0,3,0.600000000000001,5
NCT01471210,"Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",PHASE1,Urelumab (BMS-663513),Other,Unknown,Lymphoma,COMPLETED,Bristol-Myers Squibb,2012-02,2016-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00095160,Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors,PHASE1,852A,Other,Unknown,Solid Tumor,COMPLETED,"Masonic Cancer Center, University of Minnesota",2003-10,2006-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02553460,Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,"PHASE1, PHASE2","ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,St. Jude Children's Research Hospital,2016-01-29,2022-05-10,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00996060,Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies,PHASE1,"Hydralazine and Valproic Acid: Cohort -1, Hydralazine and Valproic Acid: Cohort 0, Hydralazine and Valproic Acid: Cohort 1, Hydralazine and Valproic Acid: Cohort 2, Hydralazine and Valproic Acid: Cohort 3, Hydralazine and Valproic Acid: Cohort 4, Hydralazine and Valproic Acid: Cohort 5",Other,Unknown,Solid Tumor,COMPLETED,New Mexico Cancer Research Alliance,2008-07,2012-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00412360,Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501),PHASE3,"Cyclophosphamide, Fludarabine, Cyclosporine A, Mycophenolate Mofetil",Other,Unknown,Lymphoma,COMPLETED,Medical College of Wisconsin,2006-12,2014-03,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06316960,Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation,PHASE2,"Avapritinib, Azacitidine Injection, Decitabine Injection, Idarubicin Hydrochloride, Cytarabine, Granulocyte Colony-Stimulating Factor",Other,Unknown,Leukemia,RECRUITING,Children's Hospital of Soochow University,2024-03-01,2026-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06825455,Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors,EARLY_PHASE1,"Fludarabine, Cyclophosphamide",CAR-T,Unknown,Solid Tumor,NOT_YET_RECRUITING,Peking University,2025-03-01,2027-12-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04632108,"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","PHASE1, PHASE2",ASKB589 Injection,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Jiangsu Aosaikang Pharmaceutical Co., Ltd.",2021-01-28,2025-10-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03744676,A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007),PHASE2,,CAR-T,Unknown,Lymphoma,COMPLETED,"Juno Therapeutics, a Subsidiary of Celgene",2018-11-29,2023-09-22,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00006340,Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus,PHASE1,"arginine butyrate, ganciclovir",Other,Unknown,Lymphoma,COMPLETED,Boston Medical Center,1994-12,2000-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00004889,Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia,PHASE2,,Other,Unknown,Lymphoma,COMPLETED,Jonsson Comprehensive Cancer Center,1999-12,2002-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07324889,"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","PHASE1, PHASE2",CD19/BCMA CAR-T,CAR-T,"CD19, BCMA",Other,NOT_YET_RECRUITING,Yihao Wang,2026-01-31,2027-10-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,PHASE1,"Alisertib, MLN0128",Other,Unknown,Solid Tumor,COMPLETED,"University of Colorado, Denver",2016-05-13,2020-03-18,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02895490,Communication Training in Promoting Employment Retention Among Cancer Patients,NA,,Other,Unknown,Solid Tumor,TERMINATED,Virginia Commonwealth University,2014-01,2015-02,Long-term,0.05,,3,0.07471722255609645,1
NCT01820910,Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment,PHASE2,Doxycycline,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,International Extranodal Lymphoma Study Group (IELSG),2013-03,2016-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00551460,"S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia",PHASE2,"arsenic trioxide, gemtuzumab ozogamicin, mercaptopurine, methotrexate, tretinoin",Other,Unknown,Leukemia,COMPLETED,SWOG Cancer Research Network,2007-11-15,2017-06-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04168320,SBRT-based PArtial Tumor Irradiation of HYpoxic Segment,PHASE1,,Other,Unknown,Solid Tumor,TERMINATED,Klinikum Klagenfurt am Wörthersee,2018-10-30,2022-02-14,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,Universidad Nacional de Colombia,2019-08-01,2020-12-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04173533,Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT,PHASE3,"Oral azacitidine, Matched placebo",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,University of Birmingham,2019-06-14,2025-04,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06362252,A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03),"PHASE1, PHASE2","Ifinatamab deruxtecan, Atezolizumab, Carboplatin",CAR-T,Unknown,Solid Tumor,RECRUITING,Daiichi Sankyo,2024-07-22,2026-09-30,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT06646952,CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors,,18F-FDG,Other,Unknown,Solid Tumor,RECRUITING,Hua Zhu,2024-12,2026-12,Long-term,0.1,,3,0.07471722255609645,1
NCT03069352,A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,PHASE3,"Placebo, Venetoclax, Cytarabine",Other,Unknown,Leukemia,COMPLETED,AbbVie,2017-05-23,2019-02-15,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01460238,Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia,,,Other,Unknown,Leukemia,COMPLETED,Dartmouth-Hitchcock Medical Center,2011-10,2018-05,Long-term,0.1,,3,0.07471722255609645,1
NCT04425655,Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.,PHASE2,"Fludarabine, Vyxeos",Other,Unknown,Leukemia,TERMINATED,"University of California, San Diego",2020-08-05,2022-07-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02213926,"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma",PHASE2,ACP-196 (acalabrutinib),Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Acerta Pharma BV,2015-03-02,2020-12-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07003178,A Study to Evaluate the Safety and Clinical Efficacy of STR-P004,EARLY_PHASE1,STR-P004,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,Starna Therapeutics,2025-06,2026-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02856685,A Study of Mitoxantrone Hydrochloride Liposome Infusion,"PHASE1, PHASE2",Mitoxantrone Hydrochloride Liposome,Other,Unknown,Lymphoma,UNKNOWN,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",2016-08,2017-07,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04650178,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,,,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,2020-05-26,2027-04-30,Long-term,0.1,,3,0.07471722255609645,1
NCT07368478,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies",PHASE1,BC2027 for Injection,Other,Unknown,Other,RECRUITING,"Biocity Biopharmaceutics Co., Ltd.",2025-11-24,2027-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06349343,CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus,PHASE1,,CAR-T,"CD19, BCMA",Other,RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2025-02-10,2026-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00562068,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma",PHASE1,"cyclophosphamide, doxorubicin hydrochloride, prednisolone, vincristine sulfate",Other,Unknown,Lymphoma,UNKNOWN,Cancer Research UK,2007-05,2009-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03511391,CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors,PHASE2,Nivolumab or Pembrolizumab or Atezolizumab,CAR-T,Unknown,Solid Tumor,COMPLETED,"University Hospital, Ghent",2018-03-09,2022-02-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,PHASE1,"CA102N, LONSURF",Other,Unknown,Solid Tumor,COMPLETED,"Holy Stone Healthcare Co., Ltd",2019-04-09,2022-02-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04182074,Monitoring the Diagnosis and Management of Acute Leukaemia In Pregnancy Study.,,,Other,Unknown,Leukemia,COMPLETED,University of Hull,2019-11-22,2022-09-30,Long-term,0.1,,3,0.07471722255609645,1
NCT06923397,Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial,NA,,CAR-T,Unknown,Lymphoma,RECRUITING,Dana-Farber Cancer Institute,2025-06-05,2026-11-28,Long-term,0.05,,2,0.07698823195888042,1
NCT06640413,A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors,PHASE1,"[177Lu]Lu-OncoFAP-23, L19IL2",Other,Unknown,Solid Tumor,RECRUITING,Philogen S.p.A.,2025-10-31,2028-05-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02765620,PERCIST Criteria for Response Evaluation With Solid Tumors,,,Other,Unknown,Lymphoma,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,2016-04,2018-01,Long-term,0.1,,3,0.07471722255609645,1
NCT06517433,First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b,PHASE1,upifitamab rilsodotin,Other,Unknown,Solid Tumor,COMPLETED,Mersana Therapeutics,2017-12-12,2021-07-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05875649,A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure,,,Other,Unknown,Leukemia,NOT_YET_RECRUITING,"Nanfang Hospital, Southern Medical University",2023-07-02,2027-08-20,Long-term,0.1,,3,0.07471722255609645,1
NCT06561048,"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",PHASE3,"Soquelitinib, Belinostat, Pralatrexate",CAR-T,Unknown,Lymphoma,RECRUITING,"Corvus Pharmaceuticals, Inc.",2024-10-02,2026-11,Long-term,0.6,3.0,2,0.600000000000001,5
NCT03470285,Multiparametric MRI for Diagnosing Small Renal Tumors,NA,,Other,Unknown,Solid Tumor,COMPLETED,"University Hospital, Bordeaux",2018-11-27,2022-05-27,Long-term,0.05,,3,0.07471722255609645,1
NCT00364468,Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients,PHASE2,pegfilgrastim,Other,Unknown,Other,COMPLETED,"Kyowa Kirin Co., Ltd.",2006-03,2008-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04984668,A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors,"PHASE1, PHASE2","GT90001+KN046, GT90001+KN046, GT90001/KN046, GT90001+KN046, GT90001+KN046",Other,Unknown,Solid Tumor,RECRUITING,"Suzhou Kintor Pharmaceutical Inc,",2021-11-02,2025-04,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05651191,To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL,EARLY_PHASE1,Human CD19 Targeted DASH CAR-T Cells Injection,CAR-T,CD19,Leukemia,UNKNOWN,"Hrain Biotechnology Co., Ltd.",2022-10-21,2024-09-30,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04187118,Quality of Life in Lymphoma Patients One Year Post-chemotherapy,,,Other,Unknown,Lymphoma,UNKNOWN,"University Hospital, Toulouse",2020-01-28,2025-06-01,Long-term,0.1,,3,0.07471722255609645,1
NCT02378038,PNT2258 for Treatment of Patients With Richter's Transformation (Brighton),PHASE2,PNT2258,Other,Unknown,Other,TERMINATED,Sierra Oncology LLC - a GSK company,2015-08,2016-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07375355,Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China,,,Other,Unknown,Leukemia,NOT_YET_RECRUITING,Novartis Pharmaceuticals,2026-02-27,2028-12-31,Long-term,0.1,,3,0.07471722255609645,1
NCT01118026,Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma,PHASE2,"ABVD, BEACOPP",Other,Unknown,Lymphoma,COMPLETED,Alliance for Clinical Trials in Oncology,2010-09,2020-09-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06792825,HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL,PHASE2,"Tafasitamab, Rituximab, Lenalidomide",Other,Unknown,Lymphoma,RECRUITING,"Masonic Cancer Center, University of Minnesota",2025-08-07,2029-07-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00478725,Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034,PHASE1,"GW786034, oral, GW786034, IV, GW786034, radiolabeled oral",CAR-T,Unknown,Other,COMPLETED,GlaxoSmithKline,2007-07-18,2008-07-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06188676,Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL,PHASE3,"Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Prednisolone, Rituximab, Vincristine Sulfate, Filgrastim, Pegfilgrastim, Nivolumab 40 mg in 4 ml Injection",Other,Unknown,Lymphoma,RECRUITING,"National Research Center for Hematology, Russia",2022-04-01,2029-04-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00551850,"A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients",PHASE1,AV-412,Other,EGFR,Solid Tumor,COMPLETED,"AVEO Pharmaceuticals, Inc.",2007-10,2009-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07387874,A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors,,"Trastuzumab Rezetecan, Other Drugs",Other,HER2,Solid Tumor,ACTIVE_NOT_RECRUITING,Lixiaoling,2025-07-10,2027-07,Long-term,0.1,,3,0.07471722255609645,1
NCT04724018,Sacituzumab Govitecan Plus EV in Metastatic UC,"PHASE1, PHASE2","Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab",CAR-T,Unknown,Solid Tumor,RECRUITING,Dana-Farber Cancer Institute,2021-05-20,2027-02-01,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT06789718,Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance,,,Other,Unknown,Other,ACTIVE_NOT_RECRUITING,Verb Biotics LLC,2024-11-04,2024-11-22,Long-term,0.1,,3,0.07471722255609645,1
NCT00055718,Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy,PHASE2,,Other,Unknown,Leukemia,COMPLETED,Herbert Irving Comprehensive Cancer Center,2001-11,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT00422890,Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®),PHASE3,5-Azacytidin,Other,Unknown,Leukemia,COMPLETED,Technische Universität Dresden,2007-01,2009-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06457997,A Study of PHN-010 in Patients With Advanced Solid Tumors,PHASE1,PHN-010,Other,Unknown,Solid Tumor,TERMINATED,Pheon Therapeutics,2024-07-01,2025-09-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00506597,Erwinase Study in Patients With Acute Lymphoblastic Leukemia,NA,Erwinase,Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2007-05,2012-02,Long-term,0.05,,3,0.07471722255609645,1
NCT01491958,Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation,PHASE2,"atorvastatin, Tacrolimus, methotrexate",Other,Unknown,Leukemia,COMPLETED,Ohio State University Comprehensive Cancer Center,2011-12-10,2014-01-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06244485,A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors,PHASE1,"Valemetostat tosylate, T-DXd, Dato-DXd",ADC,Unknown,Solid Tumor,RECRUITING,Daiichi Sankyo,2024-02-16,2028-11-01,Long-term,0.1,1.0,0,0.17008722943722948,1
NCT04668885,CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS,PHASE2,CPX-351,Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,Case Comprehensive Cancer Center,2021-01-14,2025-10-10,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06001385,HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis,PHASE2,"Busulfan, Fludarabine, Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Melphalan, Cyclophosphamide",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Center for International Blood and Marrow Transplant Research,2023-12-08,2026-02-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07372625,"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.",PHASE1,"metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt",Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,"PMV Pharmaceuticals, Inc",2026-01-19,2027-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05177276,Selinexor Combination Ph 1 Study,"PHASE1, PHASE2","Selinexor, Irinotecan",Other,Unknown,Solid Tumor,WITHDRAWN,Martin Gutierrez,2014-09,2015-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00720876,Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma,PHASE2,vorinostat,Other,Unknown,Lymphoma,COMPLETED,City of Hope Medical Center,2008-07-23,2017-06-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05538676,Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors,,,Other,Unknown,Solid Tumor,UNKNOWN,Xiaohua Zhu,2022-12-26,2023-08-25,Long-term,0.1,,3,0.07471722255609645,1
NCT02827968,Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,PHASE1,KN035,Other,PD-L1,Solid Tumor,COMPLETED,"3D Medicines (Sichuan) Co., Ltd.",2017-01-13,2020-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01182168,Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,PHASE1,gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001),Other,Unknown,Solid Tumor,COMPLETED,Memorial Sloan Kettering Cancer Center,2010-08,2016-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05348889,First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies,"PHASE1, PHASE2",1A46 Injection,Other,"CD19, CD20",Lymphoma,TERMINATED,"Chimagen Biosciences, Ltd",2022-08-30,2024-10-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05846750,Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma,PHASE2,"Obinutuzumab, lenalidomide",Other,Unknown,Lymphoma,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2022-11-01,2026-05-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02471391,ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM),PHASE2,"ABT-199, Ibrutinib",Other,Unknown,Lymphoma,UNKNOWN,"Peter MacCallum Cancer Centre, Australia",2015-07-22,2020-11-20,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02267590,Tissue Collection for Biomarkers Determining Resistance to Ibrutinib,,,Other,Unknown,Lymphoma,UNKNOWN,Royal Marsden NHS Foundation Trust,2014-10,2016-10,Long-term,0.1,,3,0.07471722255609645,1
NCT06585514,Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus,"PHASE1, PHASE2",CD19 CAR-T cells,CAR-T,CD19,Other,RECRUITING,Beijing GoBroad Hospital,2024-10-17,2025-09-30,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT05234606,A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors,"PHASE1, PHASE2","SBT6290, SBT6290, pembrolizumab",CAR-T,HER2,Solid Tumor,WITHDRAWN,Silverback Therapeutics,2022-03,2022-03-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04182204,"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",PHASE3,"Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin",Other,Unknown,Lymphoma,COMPLETED,Hoffmann-La Roche,2020-02-07,2024-11-29,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03811652,A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors,PHASE1,MEDI7247,CAR-T,Unknown,Solid Tumor,COMPLETED,MedImmune LLC,2018-12-20,2019-12-10,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00369252,Phase I Study of Nimotuzumab in Solid Tumours,PHASE1,Nimotuzumab (TheraCIM h-R3),Other,Unknown,Other,COMPLETED,YM BioSciences,2005-06,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT06539338,A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment,PHASE1,,Other,Unknown,Lymphoma,RECRUITING,"Kite, A Gilead Company",2024-09-20,2028-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02856048,Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer,"PHASE2, PHASE3",Triptorelin (GnRHa) + Chemotherapy,Other,Unknown,Lymphoma,UNKNOWN,Assistance Publique - Hôpitaux de Paris,2016-11-23,2021-02,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT06887348,"A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3",,,CAR-T,Unknown,Solid Tumor,RECRUITING,Replimune Inc.,2025-12-12,2030-12,Long-term,0.1,,2,0.07698823195888042,1
NCT06462248,Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies,PHASE2,CUCART19,CAR-T,CD19,Lymphoma,RECRUITING,Chi Kong Li,2024-06-01,2026-12-31,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT04629326,PD-L1 Targeting Molecular Imaging of Solid Tumors,NA,,Other,PD-L1,Solid Tumor,RECRUITING,Peking University Cancer Hospital & Institute,2021-07-20,2024-11,Long-term,0.05,,3,0.07471722255609645,1
NCT01878708,A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma,EARLY_PHASE1,"PEG-L-asparaginase, Dexamethasone acetate",Other,Unknown,Lymphoma,TERMINATED,Dana-Farber Cancer Institute,2013-07,2017-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06764017,CHiR Therapy for Elderly DLBCL Intolerant to Chemo,PHASE2,CHiR-DEL,Other,Unknown,Lymphoma,RECRUITING,First Affiliated Hospital of Ningbo University,2025-02-01,2026-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01301417,Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis,,,Other,Unknown,Lymphoma,COMPLETED,novoGI,2011-02,2011-08,Long-term,0.1,,3,0.07471722255609645,1
NCT01756118,"A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia",PHASE1,BEZ235,Other,Unknown,Leukemia,COMPLETED,Goethe University,2012-06,2017-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04604691,Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD),PHASE1,Blinatumomab for Injection,Other,Unknown,Leukemia,UNKNOWN,Seoul National University Hospital,2022-02-18,2023-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03381118,Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients,PHASE2,"Cytarabine, Nivolumab, Cytarabine, Nivolumab",Other,Unknown,Leukemia,TERMINATED,St. Petersburg State Pavlov Medical University,2017-06-30,2018-09-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04282018,"Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab","PHASE1, PHASE2","BGB-10188, Zanubrutinib, Tislelizumab",Other,Unknown,Lymphoma,COMPLETED,BeiGene,2020-05-25,2024-08-28,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04161118,TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma,PHASE2,CTL019,Other,Unknown,Lymphoma,TERMINATED,University of Cologne,2021-05-12,2023-02-24,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00573690,Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors,PHASE1,"carboplatin, cisplatin, etoposide, pemetrexed disodium, sorafenib tosylate",CAR-T,Unknown,Solid Tumor,COMPLETED,UNC Lineberger Comprehensive Cancer Center,2007-09,2009-06,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04387916,A Study of KC1036 in Patients with Advanced Solid Tumors,PHASE1,KC1036,Other,Unknown,Solid Tumor,RECRUITING,"Beijing Konruns Pharmaceutical Co., Ltd.",2020-09-04,2025-10-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01850004,Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,PHASE2,Dasatinib,Other,Unknown,Leukemia,COMPLETED,Bristol-Myers Squibb,2014-01-22,2017-09-20,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00608933,Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine,PHASE3,,Other,Unknown,Solid Tumor,COMPLETED,M.D. Anderson Cancer Center,2008-06,2020-12-07,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,NA,,Other,Unknown,Lymphoma,COMPLETED,University of Washington,2014-04,2015-07,Long-term,0.05,,3,0.07471722255609645,1
NCT03556748,WB-EMS and Nutrition in Patients With Hematological Malignancies,NA,,Other,Unknown,Lymphoma,UNKNOWN,University of Erlangen-Nürnberg Medical School,2017-11-01,2019-10-31,Long-term,0.05,,3,0.07471722255609645,1
NCT00317408,Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma,NA,"busulfan, carboplatin, carmustine, cyclosporine, cytarabine, dexamethasone, etoposide phosphate, idarubicin, ifosfamide, leucovorin calcium, lomustine, melphalan, methotrexate, mitoxantrone hydrochloride, prednisolone, thiotepa, vinblastine sulfate, vindesine",CAR-T,Unknown,Lymphoma,UNKNOWN,European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma,2004-04,2014-02,Long-term,0.05,,2,0.07698823195888042,1
NCT06307925,"A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors",PHASE1,HC010,Other,Unknown,Solid Tumor,RECRUITING,HC Biopharma Inc.,2024-03-27,2025-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06754540,Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.,PHASE2,Azacitidine (AZA),Other,Unknown,Leukemia,NOT_YET_RECRUITING,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",2025-01-16,2027-01-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06589089,Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy,PHASE2,autologous hematopoietic stem cell,CAR-T,Unknown,Lymphoma,RECRUITING,Ruijin Hospital,2024-10-15,2025-08,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT07043218,A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia,PHASE1,Chimeric Antigen Receptor T Cells (CAR-T),CAR-T,Unknown,Leukemia,NOT_YET_RECRUITING,"Shanghai Tongji Hospital, Tongji University School of Medicine",2025-07-10,2026-06-30,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04040491,"PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma",PHASE4,"PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine",Other,PD-1,Lymphoma,UNKNOWN,Mingzhi Zhang,2019-09-01,2020-12-01,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT06096974,"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",PHASE1,YL-17231,Other,KRAS,Solid Tumor,RECRUITING,Shanghai YingLi Pharmaceutical Co. Ltd.,2023-10-24,2025-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05101356,A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,RECRUITING,Tianhong Li,2021-10-13,2026-01-01,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04555551,MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma,PHASE1,,CAR-T,Unknown,Multiple Myeloma,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,2020-09-08,2026-08,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05266729,Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area,PHASE2,"Polyene Phosphatidylcholine, Placebo",Other,Unknown,Other,COMPLETED,"AMIpharm Co., Ltd.",2022-03-02,2022-12-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06904131,A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors,NA,Cell therapy with bispecific antibodies,CAR-T,Unknown,Solid Tumor,RECRUITING,Obstetrics & Gynecology Hospital of Fudan University,2025-05-11,2027-12-31,Long-term,0.05,,2,0.07698823195888042,1
NCT03547037,"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers",PHASE1,"JNJ-63723283, Erdafitinib",Other,Unknown,Solid Tumor,COMPLETED,Janssen Pharmaceutical K.K.,2018-08-31,2022-07-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01309737,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",PHASE3,"CP-690,550, CP-690,550, Placebo/CP-690,550, Placebo/CP-690,550",Other,Unknown,Other,COMPLETED,Pfizer,2011-03,2013-04,Long-term,0.6,3.0,3,0.600000000000001,5
NCT05420545,A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors,PHASE1,,CAR-T,Unknown,Solid Tumor,UNKNOWN,"Chongqing Precision Biotech Co., Ltd",2021-12-31,2023-12-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04259372,Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients,,,Other,Unknown,Leukemia,COMPLETED,University of Freiburg,2016-01-01,2019-12-31,Long-term,0.1,,3,0.07471722255609645,1
NCT01957995,Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors,PHASE1,nanosomal docetaxel lipid suspension,Other,Unknown,Solid Tumor,COMPLETED,University of Southern California,2013-11-08,2014-05-29,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03889795,"Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors",PHASE1,"Metformin, Simvastatin, Digoxin",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Danae Hamouda, MD",2019-06-05,2026-12-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00006095,Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy,PHASE1,"irinotecan hydrochloride, vincristine sulfate",Other,Unknown,Solid Tumor,COMPLETED,Children's Oncology Group,2000-07,2005-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00143975,Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM),PHASE2,"Cytarabine, Mitoxantrone, Gemtuzumab Ozogamicin, All-trans-Retinoid Acid",Other,Unknown,Leukemia,COMPLETED,University of Ulm,2004-06,2007-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05930457,Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors,PHASE1,"2.5-3.5mCi 64Cu-FAPI-XT117, 3.5-4.5mCi 64Cu-FAPI-XT117, 4.5-5.5mCi 64Cu-FAPI-XT117",Other,Unknown,Solid Tumor,COMPLETED,The First Affiliated Hospital of Guangzhou Medical University,2023-07-26,2023-10-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06013501,The Effect of Puppet Show on Pain and Fear During Subcutaneous Injection in Children With Leukemia,NA,,Other,Unknown,Leukemia,RECRUITING,Dokuz Eylul University,2023-01-03,2024-12-03,Long-term,0.05,,3,0.07471722255609645,1
NCT05312801,Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma,PHASE1,BAFF CAR-T,CAR-T,Unknown,Lymphoma,RECRUITING,Luminary Therapeutics,2023-11-21,2025-05-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04887012,Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL,PHASE1,,CAR-T,CD19,Lymphoma,UNKNOWN,"Second Affiliated Hospital, School of Medicine, Zhejiang University",2021-05-01,2022-05-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03509012,Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors,PHASE1,"Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, Cisplatin (dose level 1), Cisplatin (dose level 2)",CAR-T,Unknown,Solid Tumor,COMPLETED,AstraZeneca,2018-05-02,2020-12-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06113081,Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma,,,Other,Unknown,Lymphoma,COMPLETED,Fondazione Italiana Linfomi - ETS,2024-06-06,2025-10-10,Long-term,0.1,,3,0.07471722255609645,1
NCT00714181,Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors,PHASE1,"hydroxychloroquine, temozolomide",Other,Unknown,Solid Tumor,COMPLETED,Abramson Cancer Center at Penn Medicine,2008-06,2011-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00316511,Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma,PHASE1,Aroplatin,Other,Unknown,Lymphoma,COMPLETED,Agenus Inc.,2006-03,2008-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01553071,Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,PHASE1,Fenretinide (4-HPR) plus Intravenous Safingol,Other,Unknown,Solid Tumor,TERMINATED,South Plains Oncology Consortium,2016-11,2020-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00723099,Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer,PHASE2,"Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil",Other,Unknown,Lymphoma,COMPLETED,Fred Hutchinson Cancer Center,2008-06-25,2018-07-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00544063,"Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer",PHASE1,"irinotecan hydrochloride, oxaliplatin",Other,Unknown,Solid Tumor,UNKNOWN,Institut du Cancer de Montpellier - Val d'Aurelle,2006-10,2011-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06520163,Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma,PHASE3,"Etoposide, Cytarabine, PEG-rhG-CSF, G-CSF, G-CSF",Other,Unknown,Lymphoma,RECRUITING,The Affiliated People's Hospital of Ningbo University,2024-08-01,2026-08,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04833114,"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)",PHASE3,"Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide",CAR-T,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,GWT-TUD GmbH,2021-04-30,2025-12-31,Long-term,0.6,3.0,2,0.600000000000001,5
NCT04605614,64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression,PHASE1,,Other,Unknown,Other,WITHDRAWN,City of Hope Medical Center,2022-08-15,2024-10-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00898716,Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan,PHASE1,BMS-754807,Other,Unknown,Solid Tumor,COMPLETED,Bristol-Myers Squibb,2009-09,2011-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00498316,Cord Blood Expansion on Mesenchymal Stem Cells,PHASE1,"Busulfan, Fludarabine, Rituximab, Cyclophosphamide, Clofarabine, Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF",Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2007-07-03,2016-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06041516,Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas,PHASE1,ADCT-701,CAR-T,Unknown,Solid Tumor,RECRUITING,National Cancer Institute (NCI),2024-06-17,2027-10-30,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT07134504,Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico.,,,Other,Unknown,Lymphoma,COMPLETED,Instituto Mexicano del Seguro Social,2025-07-20,2025-07-30,Long-term,0.1,,3,0.07471722255609645,1
NCT06811233,"Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study",PHASE2,"DMSA, Ca-EDTA, Magnesium Sulfate, Multivitamin",Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2025-05-08,2029-08-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03894852,SRSF2 Gene Mutation in Patients With t-MDS/AML,,,Other,Unknown,Leukemia,COMPLETED,Zeinab Albadry Mohammed Zahran,2019-06-02,2019-12-29,Long-term,0.1,,3,0.07471722255609645,1
NCT06635785,"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","PHASE1, PHASE2",AI-081,Bispecific,PD-1,Solid Tumor,RECRUITING,"OncoC4, Inc.",2025-03-26,2026-06-30,Long-term,0.3,1.0,1,0.14954199134199123,3
NCT00499343,G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients,PHASE2,"Etoposide, G-CSF, GM-CSF, Isophosphamide, Rituximab",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2004-01,2008-10,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06911008,MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers,PHASE1,,Other,Unknown,Solid Tumor,RECRUITING,Mayo Clinic,2025-11-07,2027-04-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05036564,Diagnosis; Objective RespOnse; THErApy,NA,,Other,Unknown,Lymphoma,RECRUITING,IRCCS San Raffaele,2020-10-16,2026-07-31,Long-term,0.05,,3,0.07471722255609645,1
NCT04954599,Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI,"PHASE1, PHASE2","CP-506, Carboplatin, Immune checkpoint inhibitor",CAR-T,Unknown,Solid Tumor,RECRUITING,Maastricht University Medical Center,2023-05-30,2027-02,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02857699,Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.,,,Other,Unknown,Solid Tumor,UNKNOWN,Institut Curie,2014-04,2017-06,Long-term,0.1,,3,0.07471722255609645,1
NCT05979363,"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia",PHASE2,VRD-based regimen,CAR-T,BCMA,Leukemia,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2023-08-14,2026-07-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT06615193,A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor,PHASE1,HDM2005,Other,Unknown,Lymphoma,RECRUITING,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",2024-08-12,2026-06-24,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04957693,Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period,NA,,Other,Unknown,Lymphoma,UNKNOWN,Tel-Aviv Sourasky Medical Center,2021-07-05,2025-07-01,Long-term,0.05,,3,0.07471722255609645,1
NCT06161493,ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors,PHASE1,"ZEN003694, Niraparib",Other,Unknown,Solid Tumor,WITHDRAWN,Haider Mahdi,2024-01-23,2026-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00088114,STA-4783 and Paclitaxel for Treatment of Solid Tumors,PHASE1,STA-4783/paclitaxel,Other,Unknown,Solid Tumor,COMPLETED,Synta Pharmaceuticals Corp.,2003-01,2004-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04381806,Phase I Study in Advanced Malignancies With 5-ALA,PHASE1,5-ALA,Other,Unknown,Solid Tumor,SUSPENDED,Fox Chase Cancer Center,2020-07-30,2026-02-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00363649,Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI,PHASE2,,Other,Unknown,Leukemia,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2006-09,2017-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02181478,Intra-Osseous Co-Transplant of UCB and hMSC,EARLY_PHASE1,"cyclophosphamide, fludarabine phosphate, cyclosporine, mycophenolate mofetil",Other,Unknown,Lymphoma,COMPLETED,Case Comprehensive Cancer Center,2015-07-22,2019-12-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01457885,Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen,PHASE2,Clofarabine/Busulfan x 4,Other,Unknown,Leukemia,COMPLETED,University of Michigan Rogel Cancer Center,2011-11,2014-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04689815,Oral Arsenic Trioxide for NPM1-mutated AML,PHASE2,Oral Arsenic Trioxide Formulation,Other,Unknown,Other,UNKNOWN,The University of Hong Kong,2021-01-01,2023-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01294735,Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1),PHASE1,"MK-4827, Temozolomide",Other,Unknown,Solid Tumor,COMPLETED,Merck Sharp & Dohme LLC,2011-02,2012-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04164017,Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions,NA,,Other,Unknown,Other,UNKNOWN,"Centro Hospitalar De São João, E.P.E.",2019-06-01,2020-04-01,Long-term,0.05,,3,0.07471722255609645,1
NCT00210340,A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis,PHASE1,intrathecal rituximab,Other,Unknown,Lymphoma,WITHDRAWN,International Extranodal Lymphoma Study Group (IELSG),,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT06400251,Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K),PHASE2,Ipatasertib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2019-08-08,2023-06-27,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03468751,"Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors",PHASE1,HLX10,Other,PD-1,Solid Tumor,UNKNOWN,"Henlix, Inc",2018-02-14,2020-06-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03087929,Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon,,,Other,Unknown,Lymphoma,COMPLETED,Sunnybrook Health Sciences Centre,2013-09-20,2017-03-15,Long-term,0.1,,3,0.07471722255609645,1
NCT02824029,Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,PHASE2,Ibrutinib,Other,Unknown,Lymphoma,COMPLETED,Barbara Ann Karmanos Cancer Institute,2016-06,2023-05-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03027102,Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia,PHASE1,,Other,Unknown,Leukemia,COMPLETED,"University Health Network, Toronto",2017-08-15,2024-12-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02641002,A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS),PHASE1,CC-90002,Other,Unknown,Leukemia,TERMINATED,Celgene,2016-03-01,2018-07-18,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00101153,"Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia",PHASE1,"cytarabine, daunorubicin hydrochloride, tipifarnib",Other,Unknown,Leukemia,COMPLETED,"University Health Network, Toronto",2007-04,2010-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06475937,A Study of DM001 in Patients With Advanced Solid Tumors,PHASE1,DM001,CAR-T,Unknown,Solid Tumor,RECRUITING,"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.",2024-10-24,2026-08-13,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05087745,A Clinical Study on TIL for the Treatment of Advanced Solid Tumors,EARLY_PHASE1,,Other,Unknown,Solid Tumor,RECRUITING,Shanghai Juncell Therapeutics,2021-12-10,2024-12-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00013572,"HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults",PHASE1,,Other,Unknown,Other,UNKNOWN,Walter Reed Army Institute of Research (WRAIR),,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT05191472,Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies,PHASE2,,CAR-T,BCMA,Multiple Myeloma,TERMINATED,"Alfred Chung, MD",2022-05-03,2023-12-31,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00752895,American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL,PHASE2,,Other,Unknown,Leukemia,COMPLETED,Wake Forest University Health Sciences,2008-09-01,2008-12-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05801939,Cevostamab Following CAR T Cell Therapy for RRMM,PHASE2,Cevostamab,CAR-T,Unknown,Multiple Myeloma,ACTIVE_NOT_RECRUITING,University of Pennsylvania,2023-07-11,2027-05,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT03680677,Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies,,,Other,Unknown,Leukemia,RECRUITING,Abramson Cancer Center at Penn Medicine,2018-09-21,2026-06-22,Long-term,0.1,,3,0.07471722255609645,1
NCT02797977,A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects,"PHASE1, PHASE2","SRA737, gemcitabine, cisplatin, SRA737, gemcitabine",Other,Unknown,Solid Tumor,COMPLETED,Sierra Oncology LLC - a GSK company,2016-07,2020-04-08,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06874257,Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade,,,Other,PD-1,Leukemia,RECRUITING,IRCCS Azienda Ospedaliero-Universitaria di Bologna,2024-04-17,2025-10-31,Long-term,0.1,,3,0.07471722255609645,1
NCT01299701,"A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors",PHASE1,ASA404,Other,Unknown,Solid Tumor,TERMINATED,Novartis Pharmaceuticals,2008-12,2009-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02777736,CNS Prophylaxis in Diffuse Large B-cell Lymphoma,PHASE3,Methotrexate,Other,Unknown,Lymphoma,UNKNOWN,Czech Lymphoma Study Group,2015-07,2018-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03601611,Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms,NA,Tocilizumab (RoACTEMRA®),Other,Unknown,Solid Tumor,COMPLETED,Herlev Hospital,2019-01-01,2020-01-28,Long-term,0.05,,3,0.07471722255609645,1
NCT05963971,A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors,NA,,Other,Unknown,Leukemia,RECRUITING,Columbia University,2024-03-19,2026-12-23,Long-term,0.05,,3,0.07471722255609645,1
NCT00458744,Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment,PHASE1,talotrexin,Other,Unknown,Lymphoma,WITHDRAWN,Children's Oncology Group,2007-02,2008-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04083599,GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors,"PHASE1, PHASE2","Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel",CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Genmab,2019-09-17,2025-12-30,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT03755414,Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation,PHASE1,Itacitinib,Other,Unknown,Lymphoma,COMPLETED,Washington University School of Medicine,2019-09-04,2024-04-26,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06166706,Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia,,,Other,Unknown,Other,RECRUITING,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),2024-01-29,2025-12-30,Long-term,0.1,,3,0.07471722255609645,1
NCT07407933,A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors,"PHASE1, PHASE2","YL201, Atezolizumab",CAR-T,Unknown,Solid Tumor,NOT_YET_RECRUITING,"MediLink Therapeutics (Suzhou) Co., Ltd.",2026-03,2028-11,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02100852,"TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",PHASE1,TGR-1202 + Obinutuzumab + Chlorambucil,Other,Unknown,Leukemia,COMPLETED,"TG Therapeutics, Inc.",2014-03-12,2017-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04578847,"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)",PHASE2,"Imatinib, Nilotinib, Dasatinib, Bosutinib",Other,Unknown,Leukemia,UNKNOWN,"National Research Center for Hematology, Russia",2020-01-15,2025-01-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04508647,Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma,PHASE2,"Ublituximab, Umbralisib",Other,Unknown,Lymphoma,COMPLETED,"University of Colorado, Denver",2020-11-23,2022-07-14,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07131449,Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies,,,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,The First Affiliated Hospital of Xinxiang Medical College,2025-09-01,2027-12-31,Long-term,0.1,,3,0.07471722255609645,1
NCT00420043,Effect of Food on Bioavailability of Modified Release Formulations of Imatinib,PHASE1,imatinib,Other,Unknown,Other,COMPLETED,Novartis,2006-09,2006-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00002635,Aminocamptothecin in Treating Patients With T-cell Lymphoma,PHASE2,aminocamptothecin,Other,Unknown,Lymphoma,COMPLETED,Yale University,1995-05,2000-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02203825,Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands,PHASE1,,Other,Unknown,Leukemia,COMPLETED,Celyad Oncology SA,2015-03,2018-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03166176,Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy,PHASE2,Vistusertib(AZD2014),Other,Unknown,Solid Tumor,WITHDRAWN,Samsung Medical Center,2018-03,2018-07-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00742625,"Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","PHASE1, PHASE2","daunorubicin hydrochloride, cytarabine, bortezomib",Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2008-09,2010-07,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02592876,Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma,PHASE2,"denintuzumab mafodotin, rituximab, ifosfamide, carboplatin, etoposide",CAR-T,CD19,Lymphoma,TERMINATED,Seagen Inc.,2015-10,2018-04-20,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT01979536,Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,PHASE2,"Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate",Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),2013-11-13,2021-03-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04526834,Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma,PHASE1,CD30.CAR-T,CAR-T,CD30,Lymphoma,ACTIVE_NOT_RECRUITING,Tessa Therapeutics,2021-09-08,2022-11-22,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05503134,"Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML","PHASE1, PHASE2",,Other,Unknown,Leukemia,RECRUITING,Nationwide Children's Hospital,2022-02-14,2027-02,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04282187,"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",PHASE2,"Decitabine, Ruxolitinib, Fedratinib, Pacritinib",Other,Unknown,Leukemia,RECRUITING,University of Washington,2020-03-24,2026-11-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00003993,Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma,PHASE1,bryostatin 1,Other,Unknown,Lymphoma,COMPLETED,National Institute on Aging (NIA),1999-09,2008-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00002514,Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission,PHASE3,"asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, imatinib mesylate, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate",Other,Unknown,Leukemia,COMPLETED,Eastern Cooperative Oncology Group,1993-05-07,2006-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00514306,Study of Intermittent OSI-906 Dosing,PHASE1,OSI-906,Other,Unknown,Solid Tumor,COMPLETED,Astellas Pharma Inc,2007-07-05,2010-09-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01244906,Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant,PHASE2,,Other,Unknown,Other,COMPLETED,"Northside Hospital, Inc.",2010-12,2014-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02910752,CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation,"PHASE1, PHASE2",CLAM+PBSC,Other,Unknown,Leukemia,SUSPENDED,Shanghai Jiao Tong University School of Medicine,2016-09,2023-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01703949,Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma,PHASE2,Brentuximab Vedotin,Bispecific,CD30,Lymphoma,ACTIVE_NOT_RECRUITING,University of Washington,2013-03-20,2025-06-03,Long-term,0.3,2.0,1,0.3000000000000005,3
NCT00036855,Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma,PHASE1,,Other,Unknown,Lymphoma,TERMINATED,National Cancer Institute (NCI),2002-06,2005-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03947255,A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma,PHASE2,brentuximab vedotin,Bispecific,CD30,Lymphoma,TERMINATED,Seagen Inc.,2019-10-28,2022-11-06,Long-term,0.3,2.0,1,0.3000000000000005,3
NCT05317078,"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications",PHASE1,AMG 794,Other,Unknown,Solid Tumor,TERMINATED,Amgen,2023-02-28,2023-12-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00478985,Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia,NA,,Other,Unknown,Leukemia,COMPLETED,"University Hospital, Bordeaux",2007-06,2011-12,Long-term,0.05,,3,0.07471722255609645,1
NCT03190915,Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia,PHASE2,Trametinib,Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2018-09-09,2023-03-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02752035,"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy",PHASE3,"gilteritinib, azacitidine",Other,Unknown,Leukemia,COMPLETED,"Astellas Pharma Global Development, Inc.",2016-08-01,2023-03-10,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04442425,"Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain",,,Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2020-10-27,2024-03-27,Long-term,0.1,,3,0.07471722255609645,1
NCT00075725,Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,PHASE3,"Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate",Other,Unknown,Leukemia,COMPLETED,Children's Oncology Group,2003-12-29,2010-12-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,NA,,Other,Unknown,Solid Tumor,COMPLETED,Centre Georges Francois Leclerc,2015-12-15,2015-12-15,Long-term,0.05,,3,0.07471722255609645,1
NCT03430752,Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia,,,Other,Unknown,Leukemia,COMPLETED,The University of Hong Kong,2017-09-05,2018-08-31,Long-term,0.1,,3,0.07471722255609645,1
NCT00057447,Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients,"PHASE1, PHASE2","Interferon Gamma-1b, Rituximab",Other,Unknown,Lymphoma,TERMINATED,InterMune,2003-03,,Unknown,0.3,1.0,3,0.15123598159865156,3
NCT04679038,A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",Famitinib,Other,Unknown,Solid Tumor,UNKNOWN,"Jiangsu HengRui Medicine Co., Ltd.",2021-03-17,2022-12-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01991938,Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,PHASE1,VS-5584,Other,Unknown,Lymphoma,TERMINATED,"Verastem, Inc.",2013-11,2016-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01685008,Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL),PHASE2,MOR00208 (formerly Xmab 5574),Other,CD19,Lymphoma,COMPLETED,MorphoSys AG,2013-04-23,2022-04-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00106925,Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants,,,CAR-T,Unknown,Leukemia,RECRUITING,"National Heart, Lung, and Blood Institute (NHLBI)",2005-04-22,,Unknown,0.1,,2,0.07698823195888042,1
NCT00042809,"Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors",PHASE1,"paclitaxel, erlotinib hydrochloride",Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2002-05,2007-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00722293,"A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors",PHASE1,"Doxorubicin, Pazopanib (GW786034), Epirubicin",Other,Unknown,Solid Tumor,COMPLETED,GlaxoSmithKline,2008-07-08,2012-06-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",PHASE1,"Cobimetinib, GDC-0994",Other,Unknown,Solid Tumor,COMPLETED,"Genentech, Inc.",2015-06-16,2016-12-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05547906,Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors,PHASE1,ASCA101,Other,Unknown,Solid Tumor,COMPLETED,MetaFines,2021-11-08,2024-02-29,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04546906,Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia,NA,,CAR-T,CD22,Leukemia,UNKNOWN,"Hebei Senlang Biotechnology Inc., Ltd.",2020-09-01,2022-09-01,Long-term,0.05,,2,0.07698823195888042,1
NCT00739206,Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.,PHASE2,SAR97276A,Other,Unknown,Other,TERMINATED,Sanofi,2008-08,2009-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02990104,"First Report, Five Years Experience of the Acute Leukemia Work Group",,,Other,Unknown,Leukemia,UNKNOWN,Mexican Agrupation for Hematology Study,2016-11,2017-01,Long-term,0.1,,3,0.07471722255609645,1
NCT05752552,Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours,PHASE1,DO-2,CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,DeuterOncology,2022-12-20,2025-12,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04691349,CAR-T for r/r Malignant Tumors in Children,EARLY_PHASE1,CAR-T,CAR-T,Unknown,Solid Tumor,UNKNOWN,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",2020-09-27,2021-01-26,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06378138,ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03),"PHASE2, PHASE3","ICP-248, Orelabrutinib",Other,Unknown,Lymphoma,RECRUITING,"Beijing InnoCare Pharma Tech Co., Ltd.",2024-05-15,2030-11-25,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT02718755,"Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies",PHASE2,"Fludarabine, Cytarabine, Erwinase",Other,Unknown,Other,WITHDRAWN,M.D. Anderson Cancer Center,2018-05,2021-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01760226,"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies",EARLY_PHASE1,"DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF",Other,Unknown,Lymphoma,COMPLETED,Baylor College of Medicine,2013-01,2016-08-26,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04601285,A Phase I Study of JS108 in Patients With Advanced Solid Tumors,PHASE1,JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection),Other,TROP2,Solid Tumor,TERMINATED,"Shanghai Junshi Bioscience Co., Ltd.",2020-10-28,2023-06-14,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01897415,Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer,PHASE1,,CAR-T,Unknown,Solid Tumor,COMPLETED,University of Pennsylvania,2013-07,2015-12,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT07266025,"Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study",PHASE2,"Adebrelimab, XELOX, SHR-8068",CAR-T,Unknown,Solid Tumor,NOT_YET_RECRUITING,Shanghai Zhongshan Hospital,2026-01-30,2030-06-30,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00538109,"An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",NA,Glivec®/Gleevec®,Other,Unknown,Leukemia,COMPLETED,King Faisal Specialist Hospital & Research Center,2007-10,2013-10,Long-term,0.05,,3,0.07471722255609645,1
NCT02250287,New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease,,,Other,Unknown,Other,COMPLETED,Mayo Clinic,2014-12,2016-03,Long-term,0.1,,3,0.07471722255609645,1
NCT02458014,Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease,PHASE2,,Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2015-09-14,2025-09-16,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02869516,Institut Paoli Calmettes Acute Leukemia Database,,,Other,Unknown,Leukemia,RECRUITING,Institut Paoli-Calmettes,1995-01,2030-01,Long-term,0.1,,3,0.07471722255609645,1
NCT05720052,A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma,"PHASE1, PHASE2",MS-553,Other,Unknown,Lymphoma,TERMINATED,"MingSight Pharmaceuticals, Inc",2023-02-06,2023-11-28,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06469008,A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors,PHASE1,BL-B16D1,CAR-T,Unknown,Solid Tumor,RECRUITING,"Sichuan Baili Pharmaceutical Co., Ltd.",2024-06-27,2026-07,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05951608,A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",AK127 in combination with AK112,Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,Akeso,2023-07,2025-07,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05571540,Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL,"PHASE1, PHASE2",,CAR-T,CD19,Leukemia,WITHDRAWN,Kunming Hope of Health Hospital,2022-10-01,2024-01-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT05477589,"Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML",PHASE3,"busulfan, cyclophosphamide and melphalan, BuCyMel, clofarabine, fludarabine and busulfan, CloFluBu",Other,Unknown,Leukemia,RECRUITING,Vastra Gotaland Region,2022-06-07,2029-12-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06784752,Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET,PHASE3,Octreotide LAR,Other,Unknown,Solid Tumor,RECRUITING,Novartis Pharmaceuticals,2025-05-30,2030-09-27,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04684147,Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia,PHASE2,,Other,Unknown,Leukemia,RECRUITING,Juventas Cell Therapy Ltd.,2020-12-24,2022-09-22,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00003758,Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia,PHASE2,"cytarabine, idarubicin",Other,Unknown,Leukemia,UNKNOWN,European Organisation for Research and Treatment of Cancer - EORTC,1998-12,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT06390826,Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V),PHASE2,Sunitinib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2016-11-01,2023-04-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05443126,A Study of EP0031 in Patients With Advanced RET-altered Malignancies,"PHASE1, PHASE2",EP0031,Other,Unknown,Solid Tumor,RECRUITING,Ellipses Pharma,2022-09-30,2026-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05432635,Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma,PHASE1,,CAR-T,CD19,Lymphoma,RECRUITING,City of Hope Medical Center,2023-08-01,2028-03-30,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT07270835,Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma,PHASE4,"Rituximab, Zanubrutinib",Other,Unknown,Lymphoma,RECRUITING,The First Affiliated Hospital of Soochow University,2025-11-01,2027-04,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT07224425,A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps,PHASE1,BI 3810944,Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,Boehringer Ingelheim,2026-02-13,2029-10-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00039676,"Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer",,,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2002-07-08,,Unknown,0.1,,3,0.07471722255609645,1
NCT05551117,A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors,PHASE2,"Abiraterone, Enzalutamide",CAR-T,Unknown,Solid Tumor,TERMINATED,MacroGenics,2023-06-13,2024-07-04,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT02227940,Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,PHASE1,"Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation",CAR-T,Unknown,Solid Tumor,COMPLETED,Roswell Park Cancer Institute,2015-01-08,2018-12-27,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02197650,Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase,,suspension of erythrocytes encapsulating L-asparaginase,Other,Unknown,Leukemia,NO_LONGER_AVAILABLE,ERYtech Pharma,,,Unknown,0.1,,3,0.07471722255609645,1
NCT04435691,"Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia","PHASE1, PHASE2","Azacitidine, Venetoclax",Other,Unknown,Leukemia,TERMINATED,M.D. Anderson Cancer Center,2020-07-28,2025-03-25,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05135715,"A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)",PHASE2,RC48-ADC,ADC,HER2,Other,UNKNOWN,"RemeGen Co., Ltd.",2022-04-19,2024-12-30,Long-term,0.3,2.0,0,0.3000000000000005,3
NCT06199908,AMT-562 in Patients With Selected Advanced Solid Tumors,PHASE1,AMT-562,Other,Unknown,Solid Tumor,UNKNOWN,Multitude Therapeutics (Australia) Pty Ltd,2024-05-20,2025-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07100925,A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma,PHASE1,tolododekin alfa,CAR-T,Unknown,Solid Tumor,NOT_YET_RECRUITING,"Ankyra Therapeutics, Inc",2025-12-15,2030-06,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00940225,Study of Cabozantinib (XL184) in Adults With Advanced Malignancies,PHASE2,"Cabozantinib, Placebo",Other,Unknown,Solid Tumor,COMPLETED,Exelixis,2009-09,2013-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02482168,Study of the CD40 Agonistic Monoclonal Antibody APX005M,PHASE1,APX005M,CAR-T,Unknown,Solid Tumor,COMPLETED,"Apexigen America, Inc.",2015-05,2018-06-13,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02714374,GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers,PHASE1,,Other,Unknown,Solid Tumor,TERMINATED,Andrew Lowy,2016-03-25,2019-08-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01071018,A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007),PHASE1,"MK2206 every other day, MK2206 once weekly",Other,Unknown,Solid Tumor,COMPLETED,Merck Sharp & Dohme LLC,2010-02,2011-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03531918,"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","PHASE1, PHASE2","Cladribine, Cytarabine, Gemtuzumab Ozogamicin, Mitoxantrone Hydrochloride",Other,Unknown,Leukemia,COMPLETED,Fred Hutchinson Cancer Center,2018-09-14,2021-07-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06769113,A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy,PHASE2,"HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3",Other,Unknown,Solid Tumor,RECRUITING,Shanghai Henlius Biotech,2025-01-26,2026-10-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07374120,Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting,,,Other,Unknown,Leukemia,COMPLETED,Novartis Pharmaceuticals,2024-02-01,2025-01-21,Long-term,0.1,,3,0.07471722255609645,1
NCT06652152,Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma,,,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,Ruijin Hospital,2024-10-30,2025-05-30,Long-term,0.1,,3,0.07471722255609645,1
NCT00104858,"Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",PHASE2,"Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil",Other,Unknown,Lymphoma,COMPLETED,Fred Hutchinson Cancer Center,2004-12,2018-03-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01002755,Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,PHASE2,Lenalidomide,Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2010-01-19,2018-01-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01804335,CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL),PHASE1,CD5789 0.01% Cream,Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2013-02,2015-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01008735,Gonadal Toxicity in Women With Hodgkin Lymphoma,,,Other,Unknown,Lymphoma,UNKNOWN,Gruppo Italiano Studio Linfomi,2009-07,,Unknown,0.1,,3,0.07471722255609645,1
NCT05431608,A Study of MCARH109 and MCARH125 in People With Multiple Myeloma,PHASE1,,CAR-T,Unknown,Multiple Myeloma,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,2022-06-20,2026-06-20,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00885508,A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q,PHASE2,Lenalidomide,Other,Unknown,Leukemia,UNKNOWN,Groupe Francophone des Myelodysplasies,2009-02,2015-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03514017,Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia,PHASE2,"Pembrolizumab, Ibrutinib",Other,PD-1,Leukemia,TERMINATED,H. Lee Moffitt Cancer Center and Research Institute,2019-05-31,2023-05-16,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00005040,Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma,PHASE2,arsenic trioxide,Other,Unknown,Lymphoma,COMPLETED,Memorial Sloan Kettering Cancer Center,2000-01,2001-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05691491,Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness,"PHASE1, PHASE2","Temozolomide, Tuvusertib",CAR-T,Unknown,Solid Tumor,RECRUITING,National Cancer Institute (NCI),2023-09-28,2027-03-01,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT06509490,NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors,NA,KD-025 cell injection,CAR-T,Unknown,Solid Tumor,RECRUITING,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",2024-07-17,2024-07-26,Long-term,0.05,,2,0.07698823195888042,1
NCT04827290,Assessment of the Effect of Restriction on Alimentary AGE in Progression of Chronic Kidney Disease,NA,,Other,Unknown,Other,NOT_YET_RECRUITING,Centre Hospitalier Saint Joseph Saint Luc de Lyon,2024-08-01,2025-08-01,Long-term,0.05,,3,0.07471722255609645,1
NCT04099797,C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B),PHASE1,,CAR-T,Unknown,Solid Tumor,RECRUITING,Baylor College of Medicine,2020-02-03,2027-02,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04289220,Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia,PHASE1,,CAR-T,CD19,Lymphoma,UNKNOWN,Yan'an Affiliated Hospital of Kunming Medical University,2020-03-15,2023-03-15,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06855823,A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL,"PHASE1, PHASE2",Golicitinib combined with Pomadomide,Other,Unknown,Lymphoma,RECRUITING,Sun Yat-sen University,2025-01-14,2026-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02817633,A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER),PHASE1,"TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin",CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Tesaro, Inc.",2016-07-08,2027-03-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00004049,SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors,PHASE1,apomine,Other,Unknown,Solid Tumor,COMPLETED,"Genzyme, a Sanofi Company",1999-04,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT06725758,"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","PHASE1, PHASE2",ODM-212,Other,Unknown,Other,RECRUITING,"Orion Corporation, Orion Pharma",2023-10-26,2027-12-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00445458,A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer,"PHASE1, PHASE2","HKI-272, Paclitaxel",Other,Unknown,Solid Tumor,COMPLETED,"Puma Biotechnology, Inc.",2007-09-11,2011-05,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03173248,Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation,PHASE3,"AG-120, Placebo, Azacitidine",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,Institut de Recherches Internationales Servier,2017-06-26,2021-03-18,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04781855,"Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation",PHASE1,Ibrutinib,Other,Unknown,Lymphoma,WITHDRAWN,M.D. Anderson Cancer Center,2022-07-14,2025-02-21,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00002785,"Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia",PHASE2,"asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, mesna, methotrexate, methylprednisolone, pegaspargase, prednisone, therapeutic hydrocortisone, vincristine sulfate",Other,Unknown,Leukemia,COMPLETED,Children's Oncology Group,1996-07,2000-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03657043,A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208),PHASE2,tisotumab vedotin,Other,Unknown,Solid Tumor,COMPLETED,Seagen Inc.,2019-03-20,2022-02-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07120217,"Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.",,,CAR-T,Unknown,Lymphoma,COMPLETED,Federico II University,2008-01-01,2025-08-01,Long-term,0.1,,2,0.07698823195888042,1
NCT03435250,Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss,PHASE1,"AG-270, AG-270, AG-270, docetaxel, nab-paclitaxel, gemcitabine",Other,Unknown,Lymphoma,TERMINATED,Institut de Recherches Internationales Servier,2018-03-04,2023-04-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05151718,Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents,,,Other,Unknown,Solid Tumor,RECRUITING,Institut Claudius Regaud,2021-09-30,2025-08-31,Long-term,0.1,,3,0.07471722255609645,1
NCT06149390,ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma,,consolidation with ASCT,Other,Unknown,Lymphoma,COMPLETED,Huazhong University of Science and Technology,2014-01-01,2022-01-01,Long-term,0.1,,3,0.07471722255609645,1
NCT04052997,Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma,PHASE2,Camidanlumab Tesirine,ADC,Unknown,Lymphoma,COMPLETED,ADC Therapeutics S.A.,2019-09-13,2023-01-19,Long-term,0.3,2.0,0,0.3000000000000005,3
NCT04707560,Heparin-based Wet Suction Method in EUS Fine Needle Biopsy of Solid Pancreatic Mass,NA,,Other,Unknown,Other,UNKNOWN,National Cheng-Kung University Hospital,2020-01-01,2021-09-30,Long-term,0.05,,3,0.07471722255609645,1
NCT00280982,Dendritic Cell-based Immunotherapy in Mesothelioma,PHASE1,,Other,Unknown,Other,COMPLETED,Erasmus Medical Center,2006-01,2009-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07232524,A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors,PHASE1,BL-M24D1,CAR-T,Unknown,Solid Tumor,RECRUITING,"Sichuan Baili Pharmaceutical Co., Ltd.",2025-12-10,2027-11,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06001255,ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors,PHASE2,HS-20093,Other,Unknown,Solid Tumor,RECRUITING,Hansoh BioMedical R&D Company,2024-01-18,2024-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01995578,Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse,PHASE2,low dose 5'-azacitidine,Other,Unknown,Leukemia,COMPLETED,Memorial Sloan Kettering Cancer Center,2013-12,2023-09-27,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02360215,Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases,PHASE3,Memantine,Other,Unknown,Other,COMPLETED,NRG Oncology,2015-07,2018-04-30,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03030417,Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,PHASE1,LMP744,Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),2017-02-27,2023-10-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01892540,PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer,NA,,Other,Unknown,Solid Tumor,COMPLETED,Case Comprehensive Cancer Center,2013-05,2015-06,Long-term,0.05,,3,0.07471722255609645,1
NCT06171789,PRO1107 in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",GEN1107,CAR-T,Unknown,Solid Tumor,TERMINATED,Genmab,2024-01-29,2025-08-18,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02042690,Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients,PHASE3,Chemotherapy,Other,Unknown,Leukemia,COMPLETED,Peking University,2014-07,2018-02,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06738082,Influenza Vaccine Elicited Immune Response in Immunocompromised Patients,,,Other,Unknown,Other,COMPLETED,"Insel Gruppe AG, University Hospital Bern",2024-10-15,2025-01-31,Long-term,0.1,,3,0.07471722255609645,1
NCT06056024,A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus,PHASE1,BI 3706674,Other,KRAS,Solid Tumor,COMPLETED,Boehringer Ingelheim,2023-12-06,2025-12-17,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00027924,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome,PHASE2,"busulfan, cyclosporine, fludarabine phosphate, methotrexate",Other,Unknown,Leukemia,COMPLETED,Fred Hutchinson Cancer Center,2001-10,2003-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06873659,SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors,PHASE1,SON-DP,CAR-T,Unknown,Solid Tumor,RECRUITING,Qurgen Inc.,2025-02-26,2027-04,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT01222780,"To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer",PHASE1,Marqibo,Other,Unknown,Lymphoma,COMPLETED,Acrotech Biopharma Inc.,2010-09,2014-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02495896,Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors,PHASE1,"Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation",CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,University of Southern California,2015-09-03,2021-04-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03146962,High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies,PHASE2,Vitamin C,Other,Unknown,Solid Tumor,COMPLETED,Weill Medical College of Cornell University,2017-03-29,2023-04-21,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03250962,SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma,PHASE2,"SHR-1210, Decitabine",Other,Unknown,Lymphoma,UNKNOWN,Chinese PLA General Hospital,2017-09-11,2022-07-21,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02835833,Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,PHASE1,"Nintedanib, Bevacizumab",CAR-T,Unknown,Solid Tumor,COMPLETED,University of Alabama at Birmingham,2016-06-09,2018-04-14,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03160833,A Study of HMPL-453 in Patients With Advanced Solid Malignancies,"PHASE1, PHASE2",HMPL-453,Other,Unknown,Solid Tumor,UNKNOWN,Hutchison Medipharma Limited,2017-05-23,2019-12-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03364049,Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002),PHASE1,MK-7162,Other,Unknown,Solid Tumor,COMPLETED,Merck Sharp & Dohme LLC,2017-12-06,2020-10-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06172478,A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors,PHASE2,HER3-DXd,CAR-T,HER3,Solid Tumor,RECRUITING,Daiichi Sankyo,2024-02-26,2027-09-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT06430515,The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors,NA,,Other,Unknown,Solid Tumor,RECRUITING,Wuxi People's Hospital,2023-09-01,2027-12-31,Long-term,0.05,,3,0.07471722255609645,1
NCT03881735,Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation,PHASE2,Enasidenib,Other,Unknown,Leukemia,WITHDRAWN,Roswell Park Cancer Institute,2019-12-02,2021-11-19,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00492050,Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia,PHASE2,"Bortezomib, Rituximab, Valacyclovir",Other,Unknown,Other,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,2006-08-02,2021-02-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00491491,Zevalin-beam for Aggressive Lymphoma,PHASE3,ibritumomab tiuxetan,Other,Unknown,Lymphoma,COMPLETED,Sheba Medical Center,2007-06,2015-02,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00840190,A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies,PHASE1,P1446A-05,Other,Unknown,Solid Tumor,COMPLETED,Piramal Enterprises Limited,2008-12,2011-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00002520,Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer,NA,nicotine,Other,Unknown,Lymphoma,COMPLETED,Eastern Cooperative Oncology Group,1990-12-07,2002-02,Long-term,0.05,,3,0.07471722255609645,1
NCT03799224,Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia,"PHASE2, PHASE3","Decitabine, mBU/CY and ATG, mBU/CY",Other,Unknown,Leukemia,UNKNOWN,Peking University People's Hospital,2018-12-01,2021-12-31,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT00062296,Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia,PHASE2,epirubicin hydrochloride,Other,Unknown,Lymphoma,COMPLETED,Fox Chase Cancer Center,2003-03,2005-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03797326,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005),PHASE2,Lenvatinib,Other,Unknown,Solid Tumor,COMPLETED,Merck Sharp & Dohme LLC,2019-02-12,2024-10-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00868478,The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL),"PHASE1, PHASE2",Milatuzumab,Other,Unknown,Leukemia,UNKNOWN,Kaplan Medical Center,2009-04,2011-04,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04282343,DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer,NA,,Other,Unknown,Leukemia,COMPLETED,Barbara Ann Karmanos Cancer Institute,2020-02-25,2022-10-21,Long-term,0.05,,3,0.07471722255609645,1
NCT04626843,Intermittent Fasting and CLL/SLL,PHASE1,,Other,Unknown,Lymphoma,COMPLETED,Eleah Stringer,2021-02-03,2022-10-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04746235,"Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia",PHASE2,"Decitabine and Cedazuridine, Venetoclax",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,2021-02-22,2026-10-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02409108,Perfusion-Induced Hyperthermia for Metastatic Carcinoma,NA,,CAR-T,Unknown,Solid Tumor,COMPLETED,Jonathan Kiev,2015-07,2018-04,Long-term,0.05,,2,0.07698823195888042,1
NCT02523976,Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,PHASE2,"Dasatinib, prednisone, cyclophosphamide, daunorubicin, vincristine, cytarabine, mercaptopurine, methotrexate, dexamethasone, mitoxantrone, etoposide",Other,Unknown,Leukemia,COMPLETED,"Institute of Hematology & Blood Diseases Hospital, China",2015-08-01,2021-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03529110,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",PHASE3,"Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)",Other,HER2,Solid Tumor,ACTIVE_NOT_RECRUITING,Daiichi Sankyo,2018-08-09,2021-05-21,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00041210,Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma,PHASE3,"ABVD regimen, Stanford V regimen, dacarbazine, doxorubicin hydrochloride, etoposide, mechlorethamine hydrochloride, prednisone, vinblastine sulfate, vincristine sulfate",CAR-T,Unknown,Lymphoma,UNKNOWN,Mount Vernon Cancer Centre at Mount Vernon Hospital,2001-10,,Unknown,0.6,3.0,2,0.600000000000001,5
NCT00616213,PR104 and G-CSF in Treating Patients With Solid Tumors,PHASE1,PR104,Other,Unknown,Solid Tumor,COMPLETED,"Proacta, Incorporated",2008-02,2008-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,PHASE1,Sirolimus,CAR-T,Unknown,Solid Tumor,COMPLETED,Roswell Park Cancer Institute,2012-03,2016-07,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05653882,A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors,PHASE1,,CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Asher Biotherapeutics, Inc.",2023-01-04,2026-08,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04074759,FPT155 in Patients With Advanced Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,TERMINATED,"Five Prime Therapeutics, Inc.",2018-10-18,2021-08-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02381080,Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,PHASE1,"Ibrutinib, Erythromycin, Voriconazole",Other,Unknown,Leukemia,COMPLETED,"Janssen Research & Development, LLC",2015-05-19,2016-06-24,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00003255,Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia,PHASE2,"carboplatin, topotecan hydrochloride",CAR-T,Unknown,Leukemia,COMPLETED,Alliance for Clinical Trials in Oncology,1999-11,2006-12,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT06355908,IL13Rα2 CAR-T for Patients With r/r Glioma,PHASE1,,CAR-T,Unknown,Other,SUSPENDED,Yang Zhang,2024-03-21,2026-05-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05873608,Communication Issues in Patient and Provider Discussions of Immunotherapy,NA,,Other,Unknown,Other,RECRUITING,Emory University,2016-10-06,2026-09-17,Long-term,0.05,,3,0.07471722255609645,1
NCT01337050,Asian Phase I Study Of PF-03446962,PHASE1,PF-03446962,Other,Unknown,Other,COMPLETED,Pfizer,2011-07,2013-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02992210,Study on GD2 Positive Solid Tumors by 4SCAR-GD2,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,RECRUITING,Shenzhen Geno-Immune Medical Institute,2025-05-01,2028-06,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT05015010,Alectinib in Neo-adjuvant Treatment of Stage III NSCLC,PHASE2,Alectinib,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Gruppo Oncologico Italiano di Ricerca Clinica,2021-05-20,2024-12-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04455620,BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors,"PHASE1, PHASE2",,Other,Unknown,Solid Tumor,TERMINATED,BioNTech SE,2021-01-26,2024-05-28,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05133882,A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML,"PHASE1, PHASE2",Clifutinib Besylate,Other,Unknown,Leukemia,RECRUITING,"Sunshine Lake Pharma Co., Ltd.",2022-10-31,2026-05-15,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05492682,START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer,PHASE1,"PeptiCRAd-1, Cyclophosphamide, Pembrolizumab",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Valo Therapeutics Oy,2023-02-02,2026-10-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00631059,Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients,NA,,Other,Unknown,Leukemia,TERMINATED,"University of California, Irvine",2008-03,,Unknown,0.05,,3,0.07471722255609645,1
NCT03479918,R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS),PHASE3,"R-DA-EPOCH-21, R-BL-M-04, R-DA-EPOCH-21 + auto-SCT, R-BL-M-04 + auto-SCT",Other,Unknown,Lymphoma,UNKNOWN,Elena N.Parovichnikova,2018-03-15,2021-03-15,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04008797,A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor,"PHASE1, PHASE2","E7386, Lenvatinib, Doxorubicin, Paclitaxel",CAR-T,Unknown,Solid Tumor,RECRUITING,Eisai Inc.,2019-07-11,2027-08-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02420210,"Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma",PHASE2,"Bendamustine Hydrochloride, Dexamethasone",Other,Unknown,Lymphoma,TERMINATED,University of Chicago,2015-11,2016-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05628623,Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment,PHASE2,"Cytarabine, Venetoclax, CPX-351, Azacitidine",Other,Unknown,Leukemia,NOT_YET_RECRUITING,Eastern Cooperative Oncology Group,2024-10-23,2026-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00996359,Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation,PHASE1,,Other,Unknown,Lymphoma,TERMINATED,University of Medicine and Dentistry of New Jersey,2009-10,2011-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06802315,"Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)",PHASE2,"Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)",Other,Unknown,Leukemia,RECRUITING,University of Illinois at Chicago,2025-02-04,2030-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05692908,An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis,PHASE1,,Bispecific,Unknown,Other,WITHDRAWN,"Sorrento Therapeutics, Inc.",2023-09,2024-09,Long-term,0.1,1.0,1,0.14954199134199123,1
NCT00716417,Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours,PHASE1,"BIBW 2992, BIBW 2992",Other,Unknown,Other,COMPLETED,Boehringer Ingelheim,2008-07-01,2010-07-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06517017,"Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma",PHASE2,Isatuximab,Other,Unknown,Leukemia,RECRUITING,University of Utah,2025-10-09,2026-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00880191,Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy,PHASE3,"dexamethasone, gabapentin",Other,Unknown,Solid Tumor,COMPLETED,Alliance for Clinical Trials in Oncology,2009-04,2011-03,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06733610,CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.,PHASE1,,CAR-T,"CD19, BCMA",Other,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2024-12-05,2026-02-05,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00169520,SB-715992 In Combination With Docetaxel In Patients With Solid Tumors,PHASE1,"docetaxel, SB-715992",Other,Unknown,Solid Tumor,COMPLETED,GlaxoSmithKline,2004-06,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT00057720,TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer,PHASE3,"TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection",Other,Unknown,Solid Tumor,COMPLETED,Telik,2003-06,2006-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT07153796,A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia,PHASE2,"Blinatumomab, Mini-CVD, MTX/ARA-C",Other,Unknown,Leukemia,NOT_YET_RECRUITING,M.D. Anderson Cancer Center,2026-02-28,2031-09-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07196579,Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors,PHASE1,KXV01 TCR Lentinvivo Injection,Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,TCRx Therapeutics Co.Ltd,2025-10-01,2026-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02398747,Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies,PHASE1,AZD2014,Other,Unknown,Other,COMPLETED,AstraZeneca,2015-03-17,2024-04-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01261247,Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,PHASE2,panobinostat,Other,Unknown,Lymphoma,COMPLETED,Mayo Clinic,2011-01-17,2016-05-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00289549,"Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)",PHASE2,forodesine hydrochloride (BCX-1777),Other,Unknown,Leukemia,COMPLETED,BioCryst Pharmaceuticals,2005-06,2009-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00117455,A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma,PHASE2,"pegfilgrastim, filgrastim",Other,Unknown,Lymphoma,COMPLETED,Amgen,,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT01188915,Personalised Program for Women Treated for Hodgkin Disease,NA,,Other,Unknown,Solid Tumor,TERMINATED,Institut Paoli-Calmettes,2010-07,2016-09,Long-term,0.05,,3,0.07471722255609645,1
NCT05994235,Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma,PHASE2,"Mosunetuzumab, Tazemetostat Pill",Other,Unknown,Lymphoma,RECRUITING,Weill Medical College of Cornell University,2023-11-01,2033-10,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06089408,Weighted Blanket Use to Reduce Anxiety in Oncology Patients,NA,,Other,Unknown,Other,RECRUITING,Ohio State University Comprehensive Cancer Center,2023-08-01,2026-06-30,Long-term,0.05,,3,0.07471722255609645,1
NCT00082225,"LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)",PHASE1,,Other,Unknown,Lymphoma,TERMINATED,Baylor College of Medicine,2003-10,2006-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06630325,"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer",PHASE2,"Abemaciclib, Carboplatin, Exemestane, Fulvestrant, Gefitinib, Gemcitabine, Letrozole, Olaparib, Osimertinib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pemetrexed, Tamoxifen, Temozolomide",CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,OHSU Knight Cancer Institute,2025-06-24,2027-12-31,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00879489,Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer,"PHASE1, PHASE2",,Other,Unknown,Solid Tumor,UNKNOWN,"Quantum Immunologics, Inc.",2008-05,2011-03,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06072989,Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors,PHASE1,,CAR-T,Unknown,Solid Tumor,RECRUITING,Shanghai East Hospital,2023-10,2025-03,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02630368,A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX),"PHASE1, PHASE2","Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide",Other,Unknown,Solid Tumor,UNKNOWN,Institut Bergonié,2015-09-18,2023-05,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03355768,Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL,PHASE3,"Romidepsin, Pralatrexate",Other,Unknown,Lymphoma,WITHDRAWN,Jennifer Amengual,2018-09-01,2018-11-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02169791,Nonmyeloablative Haploidentical Transplant Followed by MLN9708,PHASE2,MLN9708,Other,Unknown,Lymphoma,COMPLETED,"Northside Hospital, Inc.",2014-07-15,2020-07-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05580770,Mirdametinib + BGB-3245 in Advanced Solid Tumors,"PHASE1, PHASE2","Mirdametinib, BGB-3245",Other,Unknown,Solid Tumor,TERMINATED,"SpringWorks Therapeutics, Inc.",2023-02-03,2025-01-15,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06522386,"GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",PHASE2,"Pirtobrutinib, Rituximab, Venetoclax",Other,Unknown,Lymphoma,RECRUITING,M.D. Anderson Cancer Center,2025-01-30,2027-02-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05641961,Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care,NA,,CAR-T,Unknown,Solid Tumor,RECRUITING,"University of California, San Francisco",2022-11-29,2026-04-30,Long-term,0.05,,2,0.07698823195888042,1
NCT06066242,Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy,NA,,Other,Unknown,Leukemia,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2023-10-01,2025-10-10,Long-term,0.05,,3,0.07471722255609645,1
NCT01891669,A Study Of PF-06263507 In Patients With Advanced Solid Tumors,PHASE1,"PF-06263507, PF-06263507",CAR-T,Unknown,Solid Tumor,TERMINATED,Pfizer,2013-08-08,2015-06-29,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00055783,Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma,PHASE2,,Other,Unknown,Lymphoma,COMPLETED,Stanford University,2002-07,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT00012194,7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors,PHASE1,"7-hydroxystaurosporine, cisplatin",Other,Unknown,Solid Tumor,TERMINATED,National Cancer Institute (NCI),2001-03,2007-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07121829,Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors,PHASE1,"Tovorafenib, Tovorafenib Drug: Pimasertib",Other,Unknown,Solid Tumor,TERMINATED,"Day One Biopharmaceuticals, Inc.",2022-05-02,2024-12-18,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00733031,"Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918",PHASE1,"AZD6918, gemcitabine, pemetrexed",Other,Unknown,Solid Tumor,TERMINATED,AstraZeneca,2008-08,2009-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04511845,A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).,PHASE1,SPYK04,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Chugai Pharmaceutical,2020-09-10,2026-09-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04261439,A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab,PHASE1,"NIZ985, Spartalizumab, Tislelizumab",Other,Unknown,Lymphoma,TERMINATED,Novartis Pharmaceuticals,2020-02-27,2023-12-27,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04267939,ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer,PHASE1,"Elimusertib (BAY1895344), Niraparib",Other,Unknown,Solid Tumor,TERMINATED,Bayer,2020-02-26,2023-12-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01169675,BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours,PHASE1,"BIBW 2992 low dose, BIBW 2992 high dose, pemetrexed, pemetrexed, BIBW 2992 high dose 6 day, pemetrexed, pemetrexed, pemetrexed, pemetrexed, BIBW 2992 low dose 6 day, BIBW 2992 medium dose 6 day, BIBW 2992 medium dose",Other,Unknown,Other,COMPLETED,Boehringer Ingelheim,2010-07,2012-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02250157,"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",PHASE1,Oratecan,Other,Unknown,Solid Tumor,COMPLETED,"Athenex, Inc.",2014-09-05,2020-03-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,PHASE1,"Cetuximab + Irinotecan, Cetuximab + Irinotecan",Other,Unknown,Solid Tumor,COMPLETED,Eli Lilly and Company,2005-08,2008-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00394381,Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome,"PHASE1, PHASE2",,Other,Unknown,Leukemia,COMPLETED,Singapore General Hospital,2006-10,2012-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06548230,A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML),"PHASE1, PHASE2","Nadunolimab, Azacitidine, Venetoclax",Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2025-03-05,2027-12-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02303028,Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours,"PHASE1, PHASE2",Topotecan and Pazopanib,Other,Unknown,Solid Tumor,COMPLETED,The Hospital for Sick Children,2015-03,2022-06-17,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02781467,"A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)",PHASE1,"Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2)",Other,Unknown,Leukemia,TERMINATED,Celularity Incorporated,2016-07-11,2017-12-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00776867,Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors,PHASE1,perifosine,Other,Unknown,Solid Tumor,COMPLETED,Memorial Sloan Kettering Cancer Center,2008-10,2017-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06796907,A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors,"PHASE1, PHASE2","GSK5733584, Dostarlimab, Bevacizumab, Anticancer therapy 3, Anticancer therapy 4",Other,Unknown,Solid Tumor,RECRUITING,GlaxoSmithKline,2025-03-04,2027-12-17,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00524407,"Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy",PHASE4,Epoetin alfa,Other,Unknown,Solid Tumor,COMPLETED,"Ortho Biotech, Inc.",1996-07,,Unknown,0.05,4.0,3,0.04999999999999991,1
NCT05376111,Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients,PHASE2,"Venetoclax, Azacitidine",Other,Unknown,Leukemia,RECRUITING,The First Affiliated Hospital of Soochow University,2022-04-01,2025-12-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00347971,Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma,PHASE1,recombinant human interleukin 21 and rituximab,Other,Unknown,Lymphoma,COMPLETED,ZymoGenetics,2006-06,2008-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01976442,Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia,,,Other,Unknown,Leukemia,COMPLETED,University of Rochester,2011-03,2016-11,Long-term,0.1,,3,0.07471722255609645,1
NCT04144842,Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,Alligator Bioscience AB,2019-12-03,2023-03-29,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00372242,Feasible Means to Address Moderately Malnourished Children Within BINP Communities,NA,,Other,Unknown,Other,COMPLETED,"International Centre for Diarrhoeal Disease Research, Bangladesh",2000-12,,Unknown,0.05,,3,0.07471722255609645,1
NCT07254754,Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma,PHASE2,Axicabtagene Ciloleucel,Other,Unknown,Lymphoma,RECRUITING,Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,2024-11-20,2027-01-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00483366,"Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors",PHASE1,"capecitabine, gemcitabine hydrochloride, imatinib mesylate",Other,Unknown,Solid Tumor,COMPLETED,University of Nebraska,2006-08-15,2009-01-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05555251,BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors,"PHASE1, PHASE2","BI-1607, BI-1607, Trastuzumab",CAR-T,HER2,Solid Tumor,TERMINATED,BioInvent International AB,2022-07-28,2024-02-07,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT00186251,High Dose Chemotherapy Followed By PBSC Rescue for HD,NA,,Other,Unknown,Other,COMPLETED,Stanford University,1998-03,,Unknown,0.05,,3,0.07471722255609645,1
NCT00101231,"Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",PHASE1,alvocidib,Other,Unknown,Leukemia,TERMINATED,National Cancer Institute (NCI),2004-10,2012-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05429502,Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors,PHASE1,"Topotecan, Temozolomide, Ribociclib",Other,Unknown,Solid Tumor,TERMINATED,Novartis Pharmaceuticals,2022-12-27,2025-02-26,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00003545,506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,PHASE2,nelarabine,Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),1998-08,2007-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00130195,Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL),PHASE2,"imatinib, cyclophosphamide, daunorubicin, vincristine, prednisolone, methotrexate, cytarabine, dexamethasone",Other,Unknown,Leukemia,COMPLETED,Japan Adult Leukemia Study Group,2002-09,2008-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05253495,Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma,PHASE2,"DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2",Other,Unknown,Lymphoma,RECRUITING,New York Medical College,2022-02-01,2027-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07030439,A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State,PHASE1,"Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd., Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.",Other,Unknown,Solid Tumor,COMPLETED,"Impact Therapeutics, Inc.",2021-07-18,2021-10-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01664975,Treatment of Peripheral T-cell Lymphoma,PHASE4,"GDPT regimen, CHOP regimen",Other,Unknown,Lymphoma,COMPLETED,Mingzhi Zhang,2011-08,2016-04,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT05757700,Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma,PHASE1,,CAR-T,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,2023-02-23,2026-02-23,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04824092,Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients,PHASE3,"Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Incyte Corporation,2021-05-11,2026-09-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03117036,Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III,,Chemotherapy,Other,Unknown,Lymphoma,RECRUITING,Samsung Medical Center,2017-03-01,2026-12-28,Long-term,0.1,,3,0.07471722255609645,1
NCT03610061,A Trial of Radiotherapy and Durvalumab in DLBCL and FL,PHASE1,Durvalumab,Other,Unknown,Lymphoma,COMPLETED,Austin Health,2018-11-01,2023-04-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01983969,Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,"PHASE1, PHASE2","Azacitidine, Vorinostat, Gemcitabine, Busulfan, Melphalan, Dexamethasone, Glutamine, Pyridoxine, Rituximab",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2013-11-07,2017-11-22,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT07190469,PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer,PHASE1,PQ203,Other,Unknown,Solid Tumor,RECRUITING,ProteinQure Inc.,2025-09-16,2028-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02682641,Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL,PHASE2,"IBRUTINIB, Rituximab",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,2016-05-18,2019-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00947856,A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study,PHASE2,brentuximab vedotin,Other,Unknown,Lymphoma,COMPLETED,Seagen Inc.,2009-07,2013-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06466122,Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi,PHASE2,"Pirtobrutinib, Venetoclax",Other,Unknown,Lymphoma,RECRUITING,Kerry Rogers,2024-11-07,2025-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03552029,Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML),PHASE1,"Quizartinib, Milademetan, Milademetan",Other,Unknown,Leukemia,TERMINATED,Daiichi Sankyo,2018-12-12,2021-04-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04801095,A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors,PHASE1,WM-S1-030,CAR-T,Unknown,Solid Tumor,UNKNOWN,Wellmarker Bio,2021-07-14,2025-08-08,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02900157,Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,MedImmune LLC,2016-08-09,2020-01-23,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06725381,A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors,PHASE1,SKB571,Other,Unknown,Solid Tumor,RECRUITING,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",2024-12-17,2026-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07213830,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","PHASE1, PHASE2",,Other,Unknown,Solid Tumor,RECRUITING,Ipsen,2026-02-28,2032-07-14,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01492569,Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting,NA,,Other,Unknown,Leukemia,WITHDRAWN,Stanford University,2012-05,2013-07,Long-term,0.05,,3,0.07471722255609645,1
NCT01766583,A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma,PHASE1,CC-292 + lenalidomide,Other,Unknown,Lymphoma,COMPLETED,The Lymphoma Academic Research Organisation,2013-02,2014-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05010694,GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results,PHASE1,GH35 Tablet,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Suzhou Genhouse Bio Co., Ltd.",2021-09-27,2023-03-22,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00066651,Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2003-07,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT04977167,Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma,PHASE1,"HG146, PD-(L)1 antibody",Other,Unknown,Lymphoma,RECRUITING,HitGen Inc.,2023-07-28,2024-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00278265,Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia,PHASE2,MTX followed by fludarabine,Other,Unknown,Leukemia,TERMINATED,German CLL Study Group,2005-06,2009-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06450067,Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia,,,Other,Unknown,Leukemia,RECRUITING,Juventas Cell Therapy Ltd.,2024-06-05,2026-06-05,Long-term,0.1,,3,0.07471722255609645,1
NCT00731328,"Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome",PHASE2,,Other,Unknown,Leukemia,COMPLETED,Asan Medical Center,2008-04,2013-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04639986,Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC),PHASE3,"Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product, Gemcitabine Injection, Vinorelbine injection",Other,HER2,Solid Tumor,ACTIVE_NOT_RECRUITING,Gilead Sciences,2020-11-23,2026-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02624570,Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy,,Midostaurin,Other,Unknown,Leukemia,NO_LONGER_AVAILABLE,Novartis Pharmaceuticals,,,Unknown,0.1,,3,0.07471722255609645,1
NCT03316573,Pembrolizumab in Neoplasms or Lymphomas,PHASE2,Pembrolizumab,Other,Unknown,Lymphoma,SUSPENDED,Dana-Farber Cancer Institute,2017-12-07,2022-08-18,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04567394,Cannabis Use Disorder Treatment Study,NA,,Other,Unknown,Other,COMPLETED,"The University of Tennessee, Knoxville",2020-12-07,2025-01-08,Long-term,0.05,,3,0.07471722255609645,1
NCT06817122,"The ""Let's Talk Tech"" Tool to Support Decision Making About Technology Use",NA,,Other,Unknown,Other,RECRUITING,University of Washington,2025-02-07,2026-04,Long-term,0.05,,3,0.07471722255609645,1
NCT04529122,A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test,,,Other,Unknown,Solid Tumor,RECRUITING,Hoffmann-La Roche,2020-08-27,2027-12-31,Long-term,0.1,,3,0.07471722255609645,1
NCT06738251,A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma,PHASE3,"SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection",CAR-T,Unknown,Other,RECRUITING,"Shanghai Hengrui Pharmaceutical Co., Ltd.",2025-02-12,2026-07,Long-term,0.6,3.0,2,0.600000000000001,5
NCT01589302,"PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia",PHASE2,ibrutinib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,"Kami Maddocks, MD",2012-05-21,2016-07-28,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06376253,A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers,PHASE1,"[68Ga]Ga-EVS459, [177Lu]Lu-EVS459",Other,Unknown,Solid Tumor,TERMINATED,Novartis Pharmaceuticals,2024-09-08,2025-07-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02561039,A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease,PHASE3,Ibandronate,Other,Unknown,Other,COMPLETED,Hoffmann-La Roche,2006-12,2008-03,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01226277,"A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma",PHASE1,GDC-0917,Other,Unknown,Lymphoma,COMPLETED,"Genentech, Inc.",2010-10,2012-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05208177,A Study of SHR-1802 in Patients With Advanced Solid Tumor,PHASE2,SHR-1802＋camrelizumab + famitinib,Other,Unknown,Solid Tumor,TERMINATED,"Jiangsu HengRui Medicine Co., Ltd.",2022-04-22,2023-08-18,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03919175,Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma,PHASE2,"Umbralisib, Rituximab",Other,Unknown,Lymphoma,TERMINATED,Massachusetts General Hospital,2019-09-01,2024-05-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05262465,Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML,NA,"Azacitidine, Venetoclax",Other,Unknown,Leukemia,UNKNOWN,guomei,2020-07-01,2023-07-01,Long-term,0.05,,3,0.07471722255609645,1
NCT00006000,"SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors",PHASE1,"cisplatin, irinotecan hydrochloride, semaxanib",Other,Unknown,Solid Tumor,COMPLETED,Ohio State University Comprehensive Cancer Center,2000-08,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT01279473,"Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)","PHASE1, PHASE2",Nilotinib,Other,Unknown,Leukemia,COMPLETED,Novartis Pharmaceuticals,2005-08,2009-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00616954,"A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT",PHASE3,ATG-F,Other,Unknown,Leukemia,TERMINATED,Hadassah Medical Organization,2008-05,2010-06,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02290522,Copenhagen Prospective Personalized Oncology (CoPPO),NA,,Other,Unknown,Solid Tumor,UNKNOWN,Ulrik Lassen,2013-05,2023-12,Long-term,0.05,,3,0.07471722255609645,1
NCT05160922,Crizotinib Continuation Clinical Study,PHASE4,crizotinib,Other,Unknown,Other,ACTIVE_NOT_RECRUITING,Pfizer,2021-12-27,2028-03-21,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT01373229,Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL),PHASE1,Lenalidomide + Plerixafor (+ Rituximab),Other,Unknown,Leukemia,COMPLETED,"David Rizzieri, MD",2012-01,2014-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00944372,"Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors",PHASE4,Indium In-111 pentetreotide,Other,Unknown,Solid Tumor,TERMINATED,Mallinckrodt,2003-07,2005-08,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT05203172,The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials,PHASE4,"Binimetinib only treatment, Encorafenib only Treatment, Encorafenib & Binimetinib Treatment, Treatment of Encorafenib & Binimetinib & Ribociclib, Treatment of Encorafenib & Binimetinib & Cetuximab",Other,Unknown,Solid Tumor,RECRUITING,Pfizer,2022-07-05,2029-07-31,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT03961672,Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,PHASE2,Duvelisib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,City of Hope Medical Center,2020-05-13,2023-07-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02787239,"Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL",PHASE3,"HLX01, Rituximab, CHOP",Other,CD20,Lymphoma,COMPLETED,Shanghai Henlius Biotech,2015-10,2018-05,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02116777,Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,"PHASE1, PHASE2","Talazoparib, Temozolomide",Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2014-05-16,2018-12-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05266612,Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors,PHASE1,"VG2025, Nivolumab Injection [Opdivo]",Other,Unknown,Solid Tumor,RECRUITING,Virogin Biotech Canada Ltd,2022-11-09,2024-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00369681,Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma,PHASE2,"Bleomycin, Dacarbazine, Doxorubicin, Vinblastine",CAR-T,Unknown,Lymphoma,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2006-05,2014-10,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT05326919,The Patient Cohort of the National Center for Precision Medicine in Leukemia,,,Other,Unknown,Leukemia,RECRUITING,Assistance Publique - Hôpitaux de Paris,2022-03-28,2042-03,Long-term,0.1,,3,0.07471722255609645,1
NCT00646854,Alemtuzumab and CHOP in T-cell Lymphoma,PHASE3,"CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab, CHOP14 chemotherapy (see specification under Arm B) plus G-CSF",Other,Unknown,Lymphoma,COMPLETED,Aarhus University Hospital,2008-06,2016-12-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01123005,Imaging and Biomarkers of Hypoxia in Solid Tumors,PHASE1,"EF5, Carbogen, Dichloroacetate",CAR-T,Unknown,Solid Tumor,TERMINATED,Stanford University,2010-12,2015-08-21,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT05982522,IN10018 Combination Therapy in Previously-treated Solid Tumors,"PHASE1, PHASE2","IN10018, Nab-paclitaxel, Tislelizumab",Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,"InxMed (Shanghai) Co., Ltd.",2025-08-13,2026-12-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,"PHASE1, PHASE2","RAD001, Sorafenib",Other,Unknown,Lymphoma,COMPLETED,Mayo Clinic,2007-08-29,2011-11-05,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01525602,Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,PHASE1,"PLX3397, Paclitaxel",Other,Unknown,Solid Tumor,COMPLETED,Daiichi Sankyo,2012-05,2017-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01416337,Absolute Bioavialability of GSK1120212,PHASE1,"GSK1120212, GSK1120212B",Other,Unknown,Solid Tumor,COMPLETED,GlaxoSmithKline,2011-06-20,2011-12-17,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01842139,Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission,PHASE1,"Montanide ISA 51 VG, poly ICLC",Other,Unknown,Leukemia,COMPLETED,University of Chicago,2011-12-05,2015-02-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00483457,Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients,,enzyme inhibitor therapy,Other,Unknown,Solid Tumor,COMPLETED,Vanderbilt-Ingram Cancer Center,2006-02,2008-11,Long-term,0.1,,3,0.07471722255609645,1
NCT01096381,Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor,,,CAR-T,Unknown,Solid Tumor,TERMINATED,Vanderbilt-Ingram Cancer Center,2010-03,2011-07,Long-term,0.1,,2,0.07698823195888042,1
NCT06682130,Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL,PHASE2,"Group A：Patients with PR or ctDNA positivity after salvage treatment, Group C: Patients with SD/PD after posterior treatment",Other,Unknown,Lymphoma,RECRUITING,The First Affiliated Hospital of Soochow University,2024-11-10,2027-11-10,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01471067,Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies,PHASE1,"Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Rituximab, ATG, Busulfan, Clofarabine",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2012-07-13,2017-04-25,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00234000,Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes,PHASE1,"arsenic trioxide, azacitidine",Other,Unknown,Leukemia,TERMINATED,Jonsson Comprehensive Cancer Center,2007-02,2009-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02003092,RX-5902 Treatment of Subjects With Triple Negative Breast Cancer,"PHASE1, PHASE2",RX-5902,Other,Unknown,Solid Tumor,TERMINATED,"Rexahn Pharmaceuticals, Inc.",2013-08,2019-10,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02255292,A Study: Pure CBD as Single-agent for Solid Tumor.,PHASE2,cannabidiol (CBD),Other,Unknown,Solid Tumor,UNKNOWN,Hadassah Medical Organization,2014-11,2015-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05645744,Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.,,,CAR-T,Unknown,Lymphoma,TERMINATED,Mustang Bio,2021-09-29,2024-04-12,Long-term,0.1,,2,0.07698823195888042,1
NCT02813330,Subcutaneous Sterile Water Injection for Relief of Low Back Pain,"PHASE1, PHASE2",,Other,Unknown,Other,UNKNOWN,"Woman's Health University Hospital, Egypt",2015-02,2016-06,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00285428,Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma,"PHASE1, PHASE2",hA20-humanized anti-CD20 antibody,Other,CD20,Lymphoma,COMPLETED,Gilead Sciences,2004-09,2007-10,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04571892,A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors,"PHASE1, PHASE2",,Other,Unknown,Solid Tumor,UNKNOWN,Shanghai East Hospital,2020-10-15,2023-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02219711,Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,PHASE1,MGCD516,Other,Unknown,Solid Tumor,COMPLETED,Mirati Therapeutics Inc.,2014-08,2022-04-27,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00143871,Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma,PHASE2,Rituximab,Other,Unknown,Lymphoma,COMPLETED,University of Michigan Rogel Cancer Center,2001-04,2006-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04328844,A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers,PHASE1,"IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,iOnctura,2020-02-25,2025-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03291353,Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia,EARLY_PHASE1,pembrolizumab,Other,Unknown,Leukemia,WITHDRAWN,Michael Boyiadzis,2017-10-17,2019-08-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03710772,"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",PHASE2,"Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Venetoclax, Vincristine Sulfate",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,2019-05-01,2027-03-22,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06197139,A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors,PHASE1,[177Lu]Lu-XT117,Other,Unknown,Solid Tumor,RECRUITING,Xinlu Wang,2024-01,2025-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00648739,Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM,"PHASE1, PHASE2",Samalizumab,Other,Unknown,Leukemia,TERMINATED,"Alexion Pharmaceuticals, Inc.",2008-06-19,2010-12-14,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02802267,Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy,PHASE2,"Inecalcitol, Placebo Oral Tablet",Other,Unknown,Leukemia,UNKNOWN,Hybrigenics Corporation,2016-06,2018-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05698667,Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer,NA,,CAR-T,Unknown,Lymphoma,COMPLETED,"Rigshospitalet, Denmark",2021-10-01,2022-05-01,Long-term,0.05,,2,0.07698823195888042,1
NCT00809367,Collection and Banking of Leukemia Cells MDS/AML,NA,,Other,Unknown,Leukemia,COMPLETED,Dana-Farber Cancer Institute,2008-10,2011-05,Long-term,0.05,,3,0.07471722255609645,1
NCT01468467,A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML),PHASE1,AC220,Other,Unknown,Leukemia,COMPLETED,Daiichi Sankyo,2012-04,2015-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05414500,Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides,PHASE1,"Mogamulizumab, Brentuximab vedotin",Other,Unknown,Lymphoma,RECRUITING,University of Alabama at Birmingham,2023-05-01,2026-04-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00102700,ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer,PHASE2,ARQ 501 in combination with gemcitabine,CAR-T,Unknown,Solid Tumor,COMPLETED,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",2005-01,2007-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00525746,Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS),,,Other,Unknown,Leukemia,UNKNOWN,M.D. Anderson Cancer Center,2006-03-31,2025-03-31,Long-term,0.1,,3,0.07471722255609645,1
NCT04181788,"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","PHASE1, PHASE2",PF-06801591,Other,PD-1,Solid Tumor,ACTIVE_NOT_RECRUITING,Pfizer,2020-03-18,2022-03-03,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01829646,Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology,NA,,Other,Unknown,Solid Tumor,RECRUITING,Universitaire Ziekenhuizen KU Leuven,2013-03,2026-03,Long-term,0.05,,3,0.07471722255609645,1
NCT05320588,A Study in Patients With Advanced Cancers,"PHASE1, PHASE2","BIO-106, Pembrolizumab",Other,Unknown,Solid Tumor,RECRUITING,BiOneCure Therapeutics Inc.,2022-03-25,2024-04,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06274788,Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment,,Omegaven® (fish oil triglycerides) Injectable Emulsion,Other,Unknown,Other,RECRUITING,Fresenius Kabi,2024-12-15,2026-03-01,Long-term,0.1,,3,0.07471722255609645,1
NCT05587088,Evaluation of the Safety and Efficacy of Esperanza Extract (PA001),"PHASE1, PHASE2","Petiveria Alliacea Preparation, Placebo",Other,Unknown,Leukemia,UNKNOWN,Hospital Universitario San Ignacio,2022-12-15,2023-03-15,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03708003,Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL,PHASE2,"Ibrutinib, Venetoclax",Other,Unknown,Leukemia,TERMINATED,Swiss Cancer Institute,2019-03-11,2025-11-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04775680,Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma,"PHASE1, PHASE2",,Other,PD-1,Lymphoma,TERMINATED,Adagene (Suzhou) Limited,2021-03-11,2023-02-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01452646,"Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia",PHASE2,,Other,Unknown,Leukemia,COMPLETED,Gruppo Italiano Malattie EMatologiche dell'Adulto,2012-01,2017-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00005986,"Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",PHASE2,"busulfan, cyclophosphamide, filgrastim, recombinant interferon alfa",Other,Unknown,Leukemia,TERMINATED,"Masonic Cancer Center, University of Minnesota",2000-08,2004-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03779854,Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant,PHASE2,"Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Tacrolimus, Methotrexate",Other,Unknown,Lymphoma,RECRUITING,Fred Hutchinson Cancer Center,2019-08-29,2027-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00003894,Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant,PHASE2,thalidomide,Other,Unknown,Solid Tumor,COMPLETED,Roswell Park Cancer Institute,1999-03,2000-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06852222,"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)",PHASE3,"Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo",Other,Unknown,Leukemia,RECRUITING,"Janssen Research & Development, LLC",2025-06-04,2029-06-22,Long-term,0.6,3.0,3,0.600000000000001,5
NCT05538195,Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,UNKNOWN,"Chongqing Precision Biotech Co., Ltd",2022-06-07,2024-12-30,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT05757219,Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy,PHASE2,Itacitinib,CAR-T,Unknown,Lymphoma,RECRUITING,H. Lee Moffitt Cancer Center and Research Institute,2023-05-19,2026-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT03496519,Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors,PHASE1,"Dose Escalation of Durvalumab and Trabectedin, Dose Expansion of Durvalumab and Trabectedin",Other,Unknown,Solid Tumor,WITHDRAWN,"University of Colorado, Denver",2018-10-01,2021-10-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00253630,Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma,PHASE2,Vorinostat,Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),2005-09,2016-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04972942,Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma,PHASE1,Daratumumab,Other,Unknown,Lymphoma,RECRUITING,New York Medical College,2023-05-22,2027-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00948883,Study of Cancers After Solid Organs Transplants,,,Other,Unknown,Solid Tumor,COMPLETED,Assistance Publique - Hôpitaux de Paris,2008-10,2011-07,Long-term,0.1,,3,0.07471722255609645,1
NCT03373305,Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas,PHASE1,"Brentuximab Vedotin, Lenalidomide",Bispecific,CD30,Lymphoma,WITHDRAWN,City of Hope Medical Center,2019-03,2019-04-26,Long-term,0.1,1.0,1,0.14954199134199123,1
NCT05006794,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",PHASE1,"zamzetoclax, Docetaxel, sacituzumab govitecan-hziy",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Gilead Sciences,2021-09-15,2029-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00765245,Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma,PHASE2,"Lenalidomide, Lenalidomide, Rituximab",Other,Unknown,Lymphoma,COMPLETED,Vanderbilt-Ingram Cancer Center,2008-10,2014-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00559039,"Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in Women",,,Other,Unknown,Solid Tumor,COMPLETED,National Institutes of Health Clinical Center (CC),2000-10,,Unknown,0.1,,3,0.07471722255609645,1
NCT06529575,Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children,,,CAR-T,Unknown,Other,RECRUITING,University of Pennsylvania,2024-08-14,2028-12,Long-term,0.1,,2,0.07698823195888042,1
NCT07338357,Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML,EARLY_PHASE1,,CAR-T,Unknown,Leukemia,NOT_YET_RECRUITING,First Affiliated Hospital of Guangxi Medical University,2026-01-05,2028-10-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00128570,An Individualized Internet-Based Health Behavior Program or a Standard Internet-Based Health Behavior Program in Preventing Cancer and Improving Physical Activity and Nutrition in Participants Who Are Physically Inactive With a Higher Body Mass Index,NA,,Other,Unknown,Solid Tumor,COMPLETED,Virginia Polytechnic Institute and State University,2006-04,2010-02,Long-term,0.05,,3,0.07471722255609645,1
NCT02839954,CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,UNKNOWN,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",2016-07,2017-07,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT06788756,L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML,"PHASE2, PHASE3","Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.",Other,Unknown,Other,RECRUITING,"Moleculin Biotech, Inc.",2025-03-12,2029-08,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT00026429,Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma,PHASE2,,Other,Unknown,Lymphoma,UNKNOWN,Pharmatech Oncology,2001-01,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT06941272,A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01),"PHASE1, PHASE2",,Other,Unknown,Solid Tumor,RECRUITING,Merck Sharp & Dohme LLC,2025-05-26,2030-12-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00792077,A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue,PHASE2,Lenalidomide,Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2008-11,2020-08-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06755775,PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma,,,Other,Unknown,Lymphoma,RECRUITING,Ruijin Hospital,2024-07-23,2029-07-23,Long-term,0.1,,3,0.07471722255609645,1
NCT05952375,"Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial",NA,Chimeric antigen receptor T cell preparation targeting Claudin18.2,CAR-T,PD-1,Solid Tumor,UNKNOWN,The Affiliated Hospital of Qingdao University,2023-03-01,2025-02-28,Long-term,0.05,,2,0.07698823195888042,1
NCT00045175,"UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",PHASE1,"7-hydroxystaurosporine, topotecan hydrochloride",Other,Unknown,Solid Tumor,COMPLETED,"University Health Network, Toronto",2002-06,2013-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04944875,Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging.,NA,,Other,Unknown,Solid Tumor,COMPLETED,TC Erciyes University,2019-05-01,2021-05-01,Long-term,0.05,,3,0.07471722255609645,1
NCT06377501,"Feasibility of a Whole-Food, Plant-Based Diet for Patients With Low-Risk Chronic Lymphocytic Leukemia (CLL)",NA,,Other,Unknown,Leukemia,COMPLETED,"University of California, San Diego",2023-03-07,2024-07-01,Long-term,0.05,,3,0.07471722255609645,1
NCT07028281,A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors,PHASE2,SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin,CAR-T,Unknown,Solid Tumor,RECRUITING,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",2025-07-08,2028-12,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT06063681,A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors,PHASE1,"SR-8541A, Immune checkpoint inhibitor (ICI)",Other,Unknown,Solid Tumor,RECRUITING,Stingray Therapeutics,2023-10-12,2025-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04911881,A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors,PHASE1,IBI321,Other,Unknown,Solid Tumor,COMPLETED,Innovent Biologics (Suzhou) Co. Ltd.,2021-06-24,2023-02-23,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01965119,Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma,PHASE2,Ruxolitinib,Other,Unknown,Lymphoma,COMPLETED,Samsung Medical Center,2013-11-15,2017-06-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05176119,Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy,PHASE4,"Nalbuphine Injection, Ketamine, Saline",Other,Unknown,Other,COMPLETED,Ain Shams University,2021-03-25,2021-06-25,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT02764281,MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma,NA,MEDA,Other,Unknown,Lymphoma,COMPLETED,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",2015-04,2020-02,Long-term,0.05,,3,0.07471722255609645,1
NCT03624530,Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants,"PHASE2, PHASE3",Tyrosine kinase inhibitor (TKIs),Other,Unknown,Leukemia,UNKNOWN,"Nanfang Hospital, Southern Medical University",2018-08,2021-07,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT01809028,Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions,NA,,Other,Unknown,Solid Tumor,COMPLETED,AdventHealth,2013-02,2014-01,Long-term,0.05,,3,0.07471722255609645,1
NCT02260661,"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",PHASE1,"AZD8835, AZD8835, AZD8835 in combination with fulvestrant, AZD8835 in combination with fulvestrant",Other,HER2,Solid Tumor,COMPLETED,AstraZeneca,2014-11,2016-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04724642,"COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency",,,CAR-T,Unknown,Other,UNKNOWN,Tel-Aviv Sourasky Medical Center,2020-12-28,2021-05-28,Long-term,0.1,,2,0.07698823195888042,1
NCT07249073,CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma,EARLY_PHASE1,CAR19-BCMA dual-target CAR-T,CAR-T,BCMA,Multiple Myeloma,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2025-03-28,2028-03-27,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00295841,Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,PHASE1,"clofarabine, cytarabine",Other,Unknown,Leukemia,COMPLETED,Wake Forest University Health Sciences,2005-02,2015-01-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00849654,Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma,PHASE1,PCI-32765,Other,Unknown,Lymphoma,COMPLETED,Pharmacyclics LLC.,2009-02,2012-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03384654,A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,PHASE2,"Daratumumab, Vincristine, Prednisone, Doxorubicin, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate",Other,Unknown,Lymphoma,COMPLETED,"Janssen Research & Development, LLC",2018-05-14,2022-09-22,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02567656,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,PHASE1,RP6530,Other,Unknown,Lymphoma,COMPLETED,Rhizen Pharmaceuticals SA,2015-09,2018-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03695757,Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG,"PHASE1, PHASE2",,Other,Unknown,Other,COMPLETED,Ajou University School of Medicine,2018-11-06,2021-01-26,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04266301,"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)",PHASE3,"Sabatolimab, Azacitidine, Placebo",Other,Unknown,Leukemia,TERMINATED,Novartis Pharmaceuticals,2020-06-08,2024-10-02,Long-term,0.6,3.0,3,0.600000000000001,5
NCT05943119,Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery,PHASE2,,CAR-T,Unknown,Solid Tumor,RECRUITING,Centre Francois Baclesse,2024-03-11,2028-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT01621542,Clinical Study of WT2725 in Patients With Advanced Malignancies,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,"Sumitomo Pharma America, Inc.",2012-07-31,2017-05-17,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03436342,Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma,EARLY_PHASE1,68Ga-Pentixafor,Other,Unknown,Lymphoma,UNKNOWN,Peking Union Medical College Hospital,2019-06-01,2020-03-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00004242,Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors,PHASE1,"fluorouracil, gemcitabine hydrochloride, oxaliplatin",Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),1999-10,2003-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01584141,Study of Lymphoma in Asia,,,Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),2011-07-05,2018-07-10,Long-term,0.1,,3,0.07471722255609645,1
NCT02160041,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,PHASE2,BGJ398,Other,Unknown,Solid Tumor,TERMINATED,Novartis Pharmaceuticals,2014-07-24,2018-04-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01116154,Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,PHASE1,"lenalidomide, vorinostat",Other,Unknown,Lymphoma,TERMINATED,City of Hope Medical Center,2010-05,2010-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00894894,"Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies",PHASE1,"MP-470, amuvatinib (MP-470)",Other,Unknown,Solid Tumor,COMPLETED,"Astex Pharmaceuticals, Inc.",2007-05,2008-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03768505,Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL),PHASE2,Zandelisib (ME-401),Other,Unknown,Lymphoma,TERMINATED,"MEI Pharma, Inc.",2019-06-25,2023-03-24,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00878722,Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy,"PHASE1, PHASE2","PXD101, idarubicin",Other,Unknown,Leukemia,COMPLETED,Valerio Therapeutics,2007-08,2009-05,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02990572,Amish/Mennonite Research Contact Registry,,,Other,Unknown,Other,RECRUITING,University of Pittsburgh,2016-10,2026-12,Long-term,0.1,,3,0.07471722255609645,1
NCT06829472,Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan,PHASE3,melphalan,Other,Unknown,Other,RECRUITING,Shanghai Jiao Tong University School of Medicine,2023-12-01,2026-07-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00169312,Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations,NA,,Other,Unknown,Solid Tumor,UNKNOWN,Josephine Ford Cancer Center,2005-08,,Unknown,0.05,,3,0.07471722255609645,1
NCT03746912,Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib,,Quizartinib Dihydrochloride,Other,Unknown,Leukemia,NO_LONGER_AVAILABLE,Daiichi Sankyo,,,Unknown,0.1,,3,0.07471722255609645,1
NCT02038361,Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array,NA,,Other,Unknown,Leukemia,COMPLETED,Assistance Publique Hopitaux De Marseille,2014-02-04,2016-05-26,Long-term,0.05,,3,0.07471722255609645,1
NCT05998642,Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma,PHASE2,"Methotrexate, Rituximab (where available), Ibrutinib",Other,Unknown,Lymphoma,RECRUITING,Canadian Cancer Trials Group,2024-02-13,2028-05-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02187861,A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL),PHASE2,"Venetoclax, Bendamustine, Rituximab",Other,Unknown,Lymphoma,COMPLETED,Hoffmann-La Roche,2014-12-01,2016-09-27,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00002869,Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia,PHASE3,"cytarabine, hydroxyurea",Other,Unknown,Leukemia,UNKNOWN,Medical Research Council,1995-04,,Unknown,0.6,3.0,3,0.600000000000001,5
NCT01019941,Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer,PHASE1,"CKD-810, Taxotere inj., CKD-810, Taxotere inj.",Other,Unknown,Solid Tumor,COMPLETED,Chong Kun Dang Pharmaceutical,2009-08,2010-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03312205,CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies,"PHASE1, PHASE2",,CAR-T,Unknown,Lymphoma,UNKNOWN,"Hebei Senlang Biotechnology Inc., Ltd.",2017-08-29,2019-08-29,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT03989466,Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia,PHASE1,Itacitinib,Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2020-01-15,2024-09-24,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02323022,Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML),PHASE3,"IAC regimen, IA regimen",Other,Unknown,Leukemia,COMPLETED,The First Affiliated Hospital of Soochow University,2014-12,2020-03,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00006451,Bone Marrow Transplantation in Treating Patients With Leukemia,PHASE3,"anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone",Other,Unknown,Lymphoma,WITHDRAWN,"Masonic Cancer Center, University of Minnesota",1996-04,2000-11,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00336531,Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation,PHASE4,itraconazole,Other,Unknown,Solid Tumor,COMPLETED,Samsung Medical Center,2006-04,2008-06,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT00840931,Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS),PHASE1,lenalidomide,Other,Unknown,Leukemia,COMPLETED,H. Lee Moffitt Cancer Center and Research Institute,2009-02-02,2014-02-17,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03521037,Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor,PHASE1,Rucaparib camsylate,Other,Unknown,Solid Tumor,COMPLETED,pharmaand GmbH,2018-02-27,2019-09-27,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06559345,"A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL",PHASE2,Cyclophosphamide,Other,Unknown,Leukemia,RECRUITING,The First Affiliated Hospital of Zhengzhou University,2025-03-17,2029-07-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06360575,Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2),PHASE2,Crizotinib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2016-05-30,2026-02-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01238939,Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer,PHASE1,NK012 and 5-FU,Other,Unknown,Solid Tumor,COMPLETED,"Nippon Kayaku Co., Ltd.",2010-08,2013-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05041257,"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers",PHASE2,Mirvetuximab soravtansine,Other,Unknown,Solid Tumor,COMPLETED,AbbVie,2021-10-19,2024-12-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02410512,A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors,PHASE1,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody",Other,PD-L1,Solid Tumor,COMPLETED,"Genentech, Inc.",2015-04-24,2019-11-22,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00400361,A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.,PHASE1,RG1507,Other,Unknown,Solid Tumor,COMPLETED,Hoffmann-La Roche,2006-04,2011-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01983761,Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation,"PHASE1, PHASE2","Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)",Other,Unknown,Lymphoma,UNKNOWN,"Targazyme, Inc.",2013-11,2014-03,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05649761,A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors,PHASE1,QL1604 injection,Other,Unknown,Solid Tumor,UNKNOWN,"Qilu Pharmaceutical Co., Ltd.",2019-05-29,2020-07-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07103486,A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,,,CAR-T,Unknown,Lymphoma,COMPLETED,Novartis Pharmaceuticals,2021-04-01,2023-01-31,Long-term,0.1,,2,0.07698823195888042,1
NCT05021770,Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma,"PHASE1, PHASE2","Orelabrutinib, Orelabrutinib, Thiotepa",Other,Unknown,Lymphoma,UNKNOWN,Huiqiang Huang,2021-12,2022-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03528941,The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib,,Lamivudine,Other,Unknown,Leukemia,COMPLETED,Gruppo Italiano Malattie EMatologiche dell'Adulto,2018-11-28,2021-03-26,Long-term,0.1,,3,0.07471722255609645,1
NCT00373529,A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II),PHASE2,clofarabine,Other,Unknown,Leukemia,COMPLETED,"Genzyme, a Sanofi Company",2006-10,2008-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06238531,A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus,PHASE1,Gusacitinib,Other,Unknown,Other,WITHDRAWN,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),2025-01-22,2025-01-22,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02566395,Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies,PHASE3,Cyclophosphamide,Other,Unknown,Lymphoma,COMPLETED,Northwell Health,2014-12,2022-01-14,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04471675,Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel,PHASE1,Albumin-bound docetaxel,Other,Unknown,Solid Tumor,UNKNOWN,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",2020-12-02,2022-12-15,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01806675,18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy,"PHASE1, PHASE2","18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2",CAR-T,Unknown,Solid Tumor,COMPLETED,Sanjiv Sam Gambhir,2013-03-04,2016-12-07,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT00233961,G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission,PHASE1,,Other,Unknown,Leukemia,COMPLETED,Herbert Irving Comprehensive Cancer Center,2005-01,2007-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01227941,MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011),PHASE1,"MK-4827 + pegylated liposomal doxorubicin, MK-4827 + pegylated liposomal doxorubicin",Other,Unknown,Solid Tumor,TERMINATED,"Tesaro, Inc.",2010-11,2011-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00956254,Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis,PHASE3,Fentanyl sublingual spray,Other,Unknown,Solid Tumor,COMPLETED,INSYS Therapeutics Inc,2009-10,2010-10,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01393366,Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy,NA,,Other,Unknown,Leukemia,COMPLETED,"University Hospital, Toulouse",2011-09,2015-12,Long-term,0.05,,3,0.07471722255609645,1
NCT00923351,"Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma","PHASE1, PHASE2","Tumor Purged/CD25 Depleted Lymphocytes, rhIL-7",Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),2007-06-02,2012-08-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01390337,A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML),PHASE1,"AC220, daunorubicin, cytarabine",Other,Unknown,Leukemia,COMPLETED,Daiichi Sankyo,2011-10,2015-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06758037,Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy,PHASE2,Drug therapy,Other,Unknown,Lymphoma,RECRUITING,First Affiliated Hospital of Ningbo University,2025-01-15,2026-12-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04996875,(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis,PHASE2,bezuclastinib,Other,Unknown,Leukemia,RECRUITING,"Cogent Biosciences, Inc.",2021-11-09,2025-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04687657,Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia,PHASE1,umbilical cord blood,Other,Unknown,Leukemia,UNKNOWN,First Affiliated Hospital Xi'an Jiaotong University,2021-02-01,2024-02-28,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00058786,Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells,PHASE1,,Other,Unknown,Leukemia,COMPLETED,Baylor College of Medicine,2002-12,2010-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04107142,Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour,PHASE1,,CAR-T,Unknown,Solid Tumor,UNKNOWN,CytoMed Therapeutics Pte Ltd,2019-12-01,2020-09-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT01796470,Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies,PHASE2,"Entospletinib, Idelalisib",Other,Unknown,Lymphoma,TERMINATED,Gilead Sciences,2013-06-20,2015-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01538641,Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas,PHASE2,"Rituximab, Gemcitabine, Oxaliplatin",Other,Unknown,Lymphoma,COMPLETED,Auxilio Mutuo Cancer Center,2003-10,2007-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06880354,A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia,PHASE1,CLL1 and CD38 Dual-Target CAR-T Cell Injection,CAR-T,Unknown,Leukemia,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2025-05-22,2028-03-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00931931,HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,Timothy Cripe,2010-03,2018-03-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02595931,M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,PHASE1,"Berzosertib, Irinotecan Hydrochloride",CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2016-07-22,2023-03-07,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03264131,BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma,PHASE2,"Brentuximab Vedotin, CHEP",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,UNC Lineberger Comprehensive Cancer Center,2018-10-11,2023-12-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05545202,"A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation",PHASE4,,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,Pharmacosmos A/S,2024-04-30,2025-02-15,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT05846737,BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT,PHASE2,,CAR-T,BCMA,Multiple Myeloma,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2023-05-29,2025-05-01,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT05404945,"Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above",PHASE2,"Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Brentuximab vedotin",CAR-T,Unknown,Lymphoma,RECRUITING,University of Virginia,2022-07-26,2027-10-03,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT06594445,HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML,PHASE1,GTB-360,Other,Unknown,Leukemia,RECRUITING,"Masonic Cancer Center, University of Minnesota",2024-11-19,2027-03-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00004895,Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery,PHASE2,octreotide acetate,Other,Unknown,Solid Tumor,COMPLETED,Northwestern University,1999-10,2002-10,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03476239,Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL),PHASE3,"Blinatumomab, Dexamthasone",Other,Unknown,Leukemia,COMPLETED,Amgen,2017-10-18,2019-08-21,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00049075,Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia,PHASE2,fludarabine phosphate,Other,Unknown,Leukemia,COMPLETED,NCIC Clinical Trials Group,2002-08-08,2005-07-22,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03685344,"Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",PHASE1,Loncastuximab Tesirine and Durvalumab,Other,Unknown,Lymphoma,TERMINATED,ADC Therapeutics S.A.,2019-02-04,2020-10-27,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06851299,The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.,PHASE2,"trop2-ADC, ADC +anti-angiogenic drug, ADC + PD1 monoclonal antibody +anti-angiogenic drug",ADC,TROP2,Solid Tumor,RECRUITING,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2025-03-01,2027-04-30,Long-term,0.3,2.0,0,0.3000000000000005,3
NCT01545063,CAre of Patients With PArenteral Nutrition At Home,,,CAR-T,Unknown,Lymphoma,COMPLETED,KU Leuven,2012-05,2013-04,Long-term,0.1,,2,0.07698823195888042,1
NCT06641648,A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.,PHASE1,NK cell,Other,Unknown,Leukemia,NOT_YET_RECRUITING,Peking University First Hospital,2024-12-01,2025-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05723055,Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma,PHASE2,"Axatilimab, Nivolumab",Other,Unknown,Lymphoma,RECRUITING,University of Utah,2023-05-03,2026-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07408258,"Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors",PHASE1,ONC-783,Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,"OncoC4, Inc.",2026-06-01,2027-06-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01106248,QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors,PHASE1,Eribulin Mesylate,Other,Unknown,Solid Tumor,COMPLETED,Eisai Limited,2009-03,2010-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02995655,CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia,PHASE1,"CX-01, Azacitidine",Other,Unknown,Leukemia,COMPLETED,Washington University School of Medicine,2017-04-07,2018-09-13,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02280785,Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas,PHASE2,Brentuximab vedotin,Bispecific,CD30,Lymphoma,COMPLETED,Samsung Medical Center,2014-11,2017-12,Long-term,0.3,2.0,1,0.3000000000000005,3
NCT06819735,Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors,"PHASE1, PHASE2","DT-7012, Immune checkpoint inhibitor",Other,Unknown,Solid Tumor,RECRUITING,Domain Therapeutics Australia Pty Ltd,2025-06-25,2027-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01652144,"A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma",PHASE2,AT7519M,Other,Unknown,Lymphoma,COMPLETED,NCIC Clinical Trials Group,2012-09-14,2014-12-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03088709,Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide,PHASE2,"Cyclophosphamide, Tacrolimus, Mycophenolate mofetil",Other,Unknown,Lymphoma,TERMINATED,Loyola University,2017-01-18,2022-01-31,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05749133,Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM,"PHASE1, PHASE2",,CAR-T,GPRC5D,Multiple Myeloma,UNKNOWN,XuYan,2023-04-10,2025-03,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT05879133,HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia,NA,,Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2023-05-17,2027-07-03,Long-term,0.05,,3,0.07471722255609645,1
NCT03213652,"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)",PHASE2,Ensartinib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2018-04-17,2025-09-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06865352,Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation,"PHASE1, PHASE2",,Other,Unknown,Leukemia,COMPLETED,Fondazione IRCCS Policlinico San Matteo di Pavia,2021-02-13,2025-01-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06421155,"Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia",NA,,Other,Unknown,Leukemia,RECRUITING,Case Comprehensive Cancer Center,2024-10-04,2027-06-14,Long-term,0.05,,3,0.07471722255609645,1
NCT01325558,A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,Altor BioScience,2011-05,2012-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05046444,Solving Riddles Through Sequencing,,,Other,Unknown,Lymphoma,RECRUITING,Munich Leukemia Laboratory,2022-01-19,2025-08-31,Long-term,0.1,,3,0.07471722255609645,1
NCT06225232,Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study,PHASE2,Psilocybin combined with Psychotherapy,Other,Unknown,Other,RECRUITING,McMaster University,2025-03,2026-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00004232,Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer,PHASE1,"cyclosporine, methylprednisolone, prednisone",Other,Unknown,Lymphoma,COMPLETED,Northwestern University,1999-10,2002-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01083706,"Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant",PHASE2,azacitidine,Other,Unknown,Leukemia,COMPLETED,Fred Hutchinson Cancer Center,2010-04,2013-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04459416,Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma,PHASE3,opioid,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,2020-06-30,2024-07-02,Long-term,0.6,3.0,3,0.600000000000001,5
NCT05519384,Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia,EARLY_PHASE1,JK500 cell injection，cyclophosphamide，Fludarabine,Other,Unknown,Leukemia,UNKNOWN,"Institute of Hematology & Blood Diseases Hospital, China",2022-09-14,2023-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06059547,Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer,PHASE2,"Nivolumab, Visugromab (CTL-002), Placebo",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,CatalYm GmbH,2023-09-06,2025-10-16,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00077558,3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome,PHASE1,"fludarabine phosphate, triapine",Other,Unknown,Leukemia,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2004-01,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT03871855,A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors,PHASE1,"SHR-1702, Camrelizumab",Other,Unknown,Solid Tumor,TERMINATED,"Jiangsu HengRui Medicine Co., Ltd.",2019-04-28,2021-06-21,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05016778,A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma,EARLY_PHASE1,GPRC5D-CAR-T,CAR-T,GPRC5D,Multiple Myeloma,UNKNOWN,Zhejiang University,2021-06-08,2024-06-30,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04132843,Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions,NA,"Gadobenate Dimeglumine, Gadobutrol",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2020-01-10,2022-09-01,Long-term,0.05,,3,0.07471722255609645,1
NCT02049515,A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07,PHASE3,"IPI-145, Ofatumumab",Other,Unknown,Lymphoma,COMPLETED,SecuraBio,2013-12,2020-06-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT02340936,"Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma","PHASE1, PHASE2","LR-ESHAP (lenalidomide 5 mg), LR-ESHAP (lenalidomide 10 mg), LR-ESHAP (lenalidomide 15 mg), LR-ESHAP (lenalidomide 20 mg)",Other,Unknown,Lymphoma,COMPLETED,Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,2011-01,2016-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00038571,Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy,PHASE2,PS341 (Bortezomib),Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2002-05,2005-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03717844,Registry for Adults With Plasma Cell Disorders (PCD's),,,Other,Unknown,Leukemia,RECRUITING,UNC Lineberger Comprehensive Cancer Center,2018-02-09,2028-02,Long-term,0.1,,3,0.07471722255609645,1
NCT05045963,Impact of Aminoglycosides in Hypotensive Septic Oncology Patients,,,Other,Unknown,Other,RECRUITING,M.D. Anderson Cancer Center,2021-01-04,2025-09-21,Long-term,0.1,,3,0.07471722255609645,1
NCT04140487,"Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm","PHASE1, PHASE2","Azacitidine, Gilteritinib, Venetoclax",Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2019-12-17,2028-09-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01379287,Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors,PHASE1,Iso-Fludelone,Other,Unknown,Solid Tumor,COMPLETED,Memorial Sloan Kettering Cancer Center,2011-06-20,2023-01-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05904106,Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML,PHASE2,"Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin",CAR-T,Unknown,Leukemia,RECRUITING,Technische Universität Dresden,2024-04-07,2028-09,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT04333914,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,PHASE2,"Autophagy inhibitor (GNS651), Avdoralimab, Monalizumab",Other,Unknown,Solid Tumor,COMPLETED,Centre Leon Berard,2020-04-15,2021-07-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00142116,Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia,PHASE2,"Thalidomide, Rituximab",Other,Unknown,Lymphoma,COMPLETED,"Steven P. Treon, MD, PhD",2003-05,2004-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06106906,A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus,"PHASE1, PHASE2",,CAR-T,CD19,Other,RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2024-06-19,2025-12,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT01137747,Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia,PHASE1,Carfilzomib,CAR-T,Unknown,Leukemia,COMPLETED,Washington University School of Medicine,2010-10,2014-08,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00548847,"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",PHASE2,,Other,Unknown,Leukemia,COMPLETED,Emory University,2007-01,2015-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02825147,Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma,PHASE2,"Pegaspargase, Methotrexate, Dexamethasone, Etoposide",Other,Unknown,Lymphoma,COMPLETED,Ruijin Hospital,2013-09,2016-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04892849,Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy,,,CAR-T,"PD-1, PD-L1",Solid Tumor,RECRUITING,University of Erlangen-Nürnberg Medical School,2021-04-30,2028-05-31,Long-term,0.1,,2,0.07698823195888042,1
NCT07238907,A Multi-center Retrospective Study of INO Treating B-ALL,,Inotuzumab Ozogamicin,Other,Unknown,Other,ACTIVE_NOT_RECRUITING,Ruijin Hospital,2022-06-01,2025-06-30,Long-term,0.1,,3,0.07471722255609645,1
NCT07192107,A Study of MHB042C in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",MHB042C for Injection,Other,Unknown,Solid Tumor,RECRUITING,Minghui Pharmaceutical (Hangzhou) Ltd,2025-10,2029-10,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00019136,Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,National Cancer Institute (NCI),1997-02,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT00090909,"Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",PHASE2,"cisplatin, dexamethasone, gemcitabine hydrochloride",Other,Unknown,Lymphoma,COMPLETED,Jonsson Comprehensive Cancer Center,2003-06,2005-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04660799,"A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)",PHASE2,"Rituximab IV, Rituximab SC, Rituximab IV, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Paracetamol, Diphenhydramine hydrochloride or alternative antihistamine",Other,CD20,Lymphoma,COMPLETED,Hoffmann-La Roche,2021-02-24,2022-05-23,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04152499,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","PHASE1, PHASE2",SKB264,CAR-T,TROP2,Solid Tumor,ACTIVE_NOT_RECRUITING,Klus Pharma Inc.,2020-02-28,2025-12-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04260932,CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients,PHASE1,,CAR-T,"CD19, CD20",Lymphoma,COMPLETED,Hebei Yanda Ludaopei Hospital,2020-03-01,2021-05-10,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06264921,A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors,PHASE1,NKT3447,CAR-T,Unknown,Solid Tumor,TERMINATED,"NiKang Therapeutics, Inc.",2024-02-23,2025-04-07,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02737085,the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL),"PHASE1, PHASE2",,CAR-T,"CD19, CD20",Lymphoma,UNKNOWN,"Southwest Hospital, China",2016-03,2019-12,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT03258099,Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients,,,Other,Unknown,Solid Tumor,UNKNOWN,Cui Yimin,2017-12-28,2019-10,Long-term,0.1,,3,0.07471722255609645,1
NCT04023916,Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.,PHASE2,Sintilimab-R-CHOP,Other,Unknown,Lymphoma,UNKNOWN,Chinese Academy of Medical Sciences,2019-12-01,2020-07-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05976906,Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors,PHASE1,,CAR-T,Unknown,Solid Tumor,UNKNOWN,Zhejiang University,2023-05-23,2025-05,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT01200004,"Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide",PHASE1,"Azacitidine, Lenalidomide, Grifola Frondosa",Other,Unknown,Solid Tumor,TERMINATED,M.D. Anderson Cancer Center,2012-04,2013-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01390584,Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma,PHASE2,"Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone",CAR-T,Unknown,Lymphoma,TERMINATED,ECOG-ACRIN Cancer Research Group,2013-05-24,2015-04-09,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00464633,Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL),PHASE2,alvocidib,Other,Unknown,Leukemia,COMPLETED,Sanofi,2007-03,2011-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02080884,An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia,,,Other,Unknown,Leukemia,COMPLETED,Hoffmann-La Roche,2014-06-24,2016-12-19,Long-term,0.1,,3,0.07471722255609645,1
NCT07147348,"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","PHASE1, PHASE2",,Other,Unknown,Solid Tumor,RECRUITING,BioNTech SE,2025-08-27,2027-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04231448,Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL,PHASE3,"R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,"Chipscreen Biosciences, Ltd.",2020-05-21,2023-01-10,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01634555,A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI,PHASE2,"Irinotecan, Folinic acid, 5-Fluorouracil",Other,Unknown,Solid Tumor,COMPLETED,Eli Lilly and Company,2012-10,2013-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02674555,"A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",PHASE1,"radio-labeled naquotinib, naquotinib",Other,EGFR,Solid Tumor,WITHDRAWN,"Astellas Pharma Global Development, Inc.",2016-11-15,2016-11-15,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01916785,OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy),PHASE2,Dasatinib,Other,Unknown,Leukemia,COMPLETED,Versailles Hospital,2009-05,2013-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03147885,Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,"PHASE1, PHASE2",Selinexor,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Barbara Ann Karmanos Cancer Institute,2017-06-20,2027-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05211336,"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",PHASE1,"Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib, Acetaminophen, Diphenhydramine",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2022-04-19,2024-06-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00144092,HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma,PHASE2,,Other,Unknown,Lymphoma,COMPLETED,Alberta Health services,2001-05,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT06724536,Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML,,,Other,Unknown,Leukemia,RECRUITING,Carmen Fava,2022-10-01,2026-10-01,Long-term,0.1,,3,0.07471722255609645,1
NCT07162571,"This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.","PHASE1, PHASE2",,CAR-T,Unknown,Lymphoma,NOT_YET_RECRUITING,"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology",2026-01-01,2030-12,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT00038844,Safety and Efficacy of Campath in Nonmyeloablative Transplantation,NA,"Campath-1 H (Alemtuzumab), Fludarabine, Cyclophosphamide, Rituximab",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2001-06,2007-12,Long-term,0.05,,3,0.07471722255609645,1
NCT07232134,The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia,PHASE3,"4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).",Other,Unknown,Leukemia,RECRUITING,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",2025-07-24,2030-07-24,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00572364,"Open Label, Dose Escalation Phase I Study of AZD2281",PHASE1,KU-0059436 (AZD2281)(PARP inhibitor),Other,Unknown,Other,COMPLETED,AstraZeneca,2007-11,2009-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01066663,Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"PHASE1, PHASE2",pyrimethamine,Other,Unknown,Lymphoma,COMPLETED,Dana-Farber Cancer Institute,2010-03,2022-02,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05436093,CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors,NA,18F-FDG,Other,CLDN18.2,Solid Tumor,UNKNOWN,Peking University Cancer Hospital & Institute,2022-06-23,2024-06,Long-term,0.05,,3,0.07471722255609645,1
NCT02112916,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,PHASE3,"Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2014-10-04,2020-03-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00003784,"S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",PHASE2,"CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate",Other,Unknown,Lymphoma,COMPLETED,SWOG Cancer Research Network,1999-05,2003-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01848652,Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.,PHASE2,infusion of MYOCET,Other,Unknown,Lymphoma,TERMINATED,"University Hospital, Brest",2013-10,2015-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00621452,"Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",PHASE1,cyclophosphamide,Other,Unknown,Lymphoma,COMPLETED,Fred Hutchinson Cancer Center,2007-08,2014-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00704938,"Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",PHASE2,"cyclophosphamide, fludarabine phosphate",Other,Unknown,Solid Tumor,TERMINATED,National Institutes of Health Clinical Center (CC),2008-06,2009-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06644755,First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors,PHASE1,DS-2243a,Other,Unknown,Solid Tumor,RECRUITING,Daiichi Sankyo,2024-11-14,2028-11-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00307255,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors,PHASE1,"gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation",Other,Unknown,Solid Tumor,COMPLETED,UNC Lineberger Comprehensive Cancer Center,2006-08,2007-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05601726,"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","PHASE1, PHASE2","ABD-3001, ABD-3001",Other,Unknown,Leukemia,RECRUITING,Advanced BioDesign,2022-11-08,2026-06,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00460278,Study of XL418 in Adults With Solid Tumors,PHASE1,XL418,Other,Unknown,Solid Tumor,SUSPENDED,Exelixis,2007-04,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT03448211,A Study of PTS for Patients With Solid Tumors,PHASE1,Para-toluenesulfonamide Injection (PTS),Other,Unknown,Solid Tumor,WITHDRAWN,PTS International Inc.,2018-05-01,2019-05-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00970411,Study of KRN951 in Patients With Solid Tumors,PHASE1,KRN951,Other,Unknown,Solid Tumor,COMPLETED,"Kyowa Kirin Co., Ltd.",2009-08,2016-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00724009,Clofarabine Bone Marrow Cytoreduction,PHASE2,Clofarabine,Other,Unknown,Leukemia,COMPLETED,University of Chicago,2007-12,2010-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00814463,Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases,PHASE2,,Other,Unknown,Solid Tumor,TERMINATED,Duke University,2008-08,2009-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03623087,SIMPLE Chemotherapy for NK Lymphoma/Leukaemia,PHASE3,"Cisplatin, Gemcitabine, Etoposide (VP-16), Dexamethasone, L-asparaginase",Other,Unknown,Lymphoma,UNKNOWN,The University of Hong Kong,2017-07-01,2020-03-14,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01169584,Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients,PHASE1,Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594),Other,Unknown,Lymphoma,COMPLETED,Jennerex Biotherapeutics,2010-08,2012-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04492033,A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients,"PHASE1, PHASE2","CTX-009 (ABL001), Paclitaxel, Irinotecan",Other,Unknown,Solid Tumor,TERMINATED,Handok Inc.,2020-06-22,2024-01-08,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06493552,Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors,"PHASE2, PHASE3","SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin",CAR-T,Unknown,Solid Tumor,RECRUITING,"Vasgene Therapeutics, Inc",2025-03-15,2029-09,Long-term,0.6,2.0,2,0.3111600000396263,5
NCT03611738,"Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC",PHASE1,"Ceritinib, Docetaxel",Other,EGFR,Solid Tumor,ACTIVE_NOT_RECRUITING,H. Lee Moffitt Cancer Center and Research Institute,2019-02-01,2025-04-28,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02733458,GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma,NA,GELAD,Other,Unknown,Lymphoma,COMPLETED,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",2016-03,2021-04,Long-term,0.05,,3,0.07471722255609645,1
NCT04763148,Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA,,,Other,Unknown,Lymphoma,COMPLETED,Herlev Hospital,2022-01-12,2022-12-01,Long-term,0.1,,3,0.07471722255609645,1
NCT01808326,"A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia",PHASE2,"chlorambucil, tablets",Other,Unknown,Leukemia,COMPLETED,GlaxoSmithKline,2013-04,2014-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01110226,Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies,PHASE1,"KML-001, Cisplatin",Other,Unknown,Solid Tumor,TERMINATED,"University of Maryland, Baltimore",2010-04-27,2015-10-22,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02352844,"Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",PHASE2,Everolimus,Other,Unknown,Solid Tumor,COMPLETED,Washington University School of Medicine,2015-10-07,2017-08-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00621244,A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies,"PHASE1, PHASE2",LBH589,Other,Unknown,Lymphoma,COMPLETED,Novartis Pharmaceuticals,2003-03-01,2009-12-03,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT05286164,Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART,PHASE2,Eltrombopag,CAR-T,Unknown,Lymphoma,UNKNOWN,Tel-Aviv Sourasky Medical Center,2022-04,2023-04,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT03647163,Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors,"PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Vyriad, Inc.",2019-04-09,2025-07-31,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02697552,Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma,PHASE1,HBI-8000,Other,Unknown,Lymphoma,COMPLETED,"HUYABIO International, LLC.",2014-03,2016-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06269133,Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients,,REGN2810,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Regeneron Pharmaceuticals,2024-02-21,2027-03-31,Long-term,0.1,,3,0.07471722255609645,1
NCT02543749,DC Vaccination in CML,"PHASE1, PHASE2",,Other,Unknown,Leukemia,TERMINATED,"Charite University, Berlin, Germany",2014-07,2022-07,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00003248,Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia,PHASE2,fludarabine phosphate,Other,Unknown,Leukemia,COMPLETED,Alliance for Clinical Trials in Oncology,1998-03,2003-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03650348,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,PHASE1,PRS-343 in Combination with Atezolizumab,Other,HER2,Solid Tumor,COMPLETED,"Pieris Pharmaceuticals, Inc.",2018-08-21,2022-08-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00064311,Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation,"PHASE1, PHASE2",ravuconazole,Other,Unknown,Lymphoma,COMPLETED,National Institutes of Health Clinical Center (CC),2003-06,,Unknown,0.3,1.0,3,0.15123598159865156,3
NCT05579132,A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002),"PHASE1, PHASE2",MK-1045,Other,Unknown,Leukemia,RECRUITING,"MSD R&D (China) Co., Ltd.",2022-11-01,2028-06-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04688463,Evaluation of Pressure Algometry in the Clinical Assessment of Acute Abdominal Pain in Children,,,Other,Unknown,Other,COMPLETED,University of Manitoba,2000-01-01,2006-06-15,Long-term,0.1,,3,0.07471722255609645,1
NCT01861314,"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",PHASE1,"Bortezomib, Decitabine, Sorafenib Tosylate",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2013-07-03,2015-11-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01800838,Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma,PHASE1,"silicon phthalocyanine 4, photodynamic therapy",Other,Unknown,Lymphoma,COMPLETED,Kevin Cooper MD,2013-04,2014-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00110058,Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia,PHASE2,"cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil",Other,Unknown,Leukemia,COMPLETED,Fred Hutchinson Cancer Center,2005-02,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT01120457,"First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers",PHASE1,BMS-936564 (Anti-CXCR4),Other,Unknown,Lymphoma,COMPLETED,Bristol-Myers Squibb,2010-08,2014-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07126301,Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting,NA,,Other,Unknown,Solid Tumor,RECRUITING,City of Hope Medical Center,2025-07-08,2027-01-01,Long-term,0.05,,3,0.07471722255609645,1
NCT06059001,"Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC",PHASE1,"OMO-103, Nab-Paclitaxel, Gemcitabine",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Peptomyc S.L.,2023-08-31,2026-05-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00004912,Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss,PHASE2,megestrol acetate,Other,Unknown,Solid Tumor,COMPLETED,Northwestern University,2000-01,2003-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02966730,Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy,EARLY_PHASE1,Ibrutinib,Other,Unknown,Lymphoma,TERMINATED,Memorial Sloan Kettering Cancer Center,2016-11,2019-06-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03449030,A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC),PHASE1,"TAK-164, 89Zr-TAK-164",Other,Unknown,Solid Tumor,TERMINATED,"Millennium Pharmaceuticals, Inc.",2018-04-23,2020-02-27,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05387265,"A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors",PHASE1,CX-904,Other,Unknown,Solid Tumor,TERMINATED,CytomX Therapeutics,2022-05-16,2025-06-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02870036,"Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors",PHASE1,"Simmitecan, 5-fluorouracil and Leucovorin Calcium, Thalidomide",Other,Unknown,Solid Tumor,UNKNOWN,"Haihe Biopharma Co., Ltd.",2016-10,2020-12,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06246071,A Study of TYK-00540 in Adult Patients With Solid Tumors,PHASE1,TYK-00540,Other,Unknown,Solid Tumor,RECRUITING,"TYK Medicines, Inc",2024-01-02,2026-12-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04850664,Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder,PHASE2,"CBOT + TAU, Sham + TAU",Other,Unknown,Other,UNKNOWN,Evon Medics LLC,2021-03-26,2022-11-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03671564,Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML),PHASE1,Milademetan,Other,Unknown,Leukemia,COMPLETED,"Daiichi Sankyo Co., Ltd.",2018-08-23,2019-09-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04086264,IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia,"PHASE1, PHASE2","Azacitidine, IMGN632, Venetoclax",Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,AbbVie,2019-11-06,2027-02,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00138164,Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,PHASE2,,Other,Unknown,Lymphoma,COMPLETED,Jonsson Comprehensive Cancer Center,2004-12,2006-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02293109,Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma,PHASE1,"carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone",CAR-T,Unknown,Lymphoma,COMPLETED,"Mehrdad Abedi, MD",2015-12-17,2017-12-13,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT06093698,An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases,PHASE1,,Other,Unknown,Solid Tumor,NOT_YET_RECRUITING,"ITabMed Co., Ltd.",2023-12-01,2026-06-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02261298,ONO-4538 Phase I Study in Patients With Solid Tumor,PHASE1,ONO-4538,Other,Unknown,Solid Tumor,COMPLETED,Ono Pharmaceutical Co. Ltd,2014-10,2015-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05763563,Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy,NA,,CAR-T,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,H. Lee Moffitt Cancer Center and Research Institute,2023-02-21,2025-01-19,Long-term,0.05,,2,0.07698823195888042,1
NCT01374139,Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects,PHASE1,"Bosutinib, Bosutinib",Other,Unknown,Leukemia,COMPLETED,Pfizer,2011-08,2011-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03200977,Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab,,,Other,Unknown,Lymphoma,COMPLETED,Bristol-Myers Squibb,2016-07-01,2022-06-03,Long-term,0.1,,3,0.07471722255609645,1
NCT04375228,Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs),PHASE2,"Rituximab, Tocilizumab",Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,Columbia University,2020-09-25,2025-05-14,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05998928,A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy,PHASE2,Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells,CAR-T,"BCMA, GPRC5D",Multiple Myeloma,RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2023-07-27,2025-07-27,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00427765,Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma,PHASE2,"Busulfan, Melphalan",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2004-12,2010-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00109707,A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies,"PHASE1, PHASE2",Nilotinib,Other,Unknown,Leukemia,COMPLETED,Novartis Pharmaceuticals,2005-04,2012-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00060671,Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma,PHASE3,"rituximab, Pixantrone (BBR 2778)",Other,Unknown,Lymphoma,TERMINATED,CTI BioPharma,2005-01,2006-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01020734,Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission,PHASE2,"busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate",Other,Unknown,Leukemia,COMPLETED,Asan Medical Center,2011-05,2015-07,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06544109,Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients,"PHASE2, PHASE3",venetoclax,Other,Unknown,Leukemia,ENROLLING_BY_INVITATION,The First Affiliated Hospital of Soochow University,2023-08-01,2025-08-01,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT02304393,A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors,PHASE1,"Atezolizumab, Selicrelumab",Other,Unknown,Solid Tumor,COMPLETED,Hoffmann-La Roche,2014-12-12,2019-11-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02736721,Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML),PHASE3,Peginterferon alfa-2a,Other,Unknown,Leukemia,COMPLETED,Hoffmann-La Roche,2003-09,2010-11,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06656221,"A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",PHASE2,"Obinutuzumab, Glofitamab, Bortezomib, Orelabrutinib",Other,Unknown,Lymphoma,NOT_YET_RECRUITING,Ruijin Hospital,2024-12-01,2026-12-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00075816,Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201),PHASE3,,Other,Unknown,Leukemia,COMPLETED,Medical College of Wisconsin,2004-01,2013-04,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03668119,A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H),PHASE2,,Other,Unknown,Solid Tumor,COMPLETED,Bristol-Myers Squibb,2018-10-31,2022-05-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03936465,Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer,PHASE1,"BMS-986158, BMS-986378",Other,Unknown,Lymphoma,COMPLETED,Dana-Farber Cancer Institute,2019-09-27,2024-03-16,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02475707,Administration of Donor MultiTAA-Specific T Cells for ALL,PHASE1,,Other,Unknown,Leukemia,COMPLETED,Baylor College of Medicine,2016-02,2019-10-29,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05849792,Internet-based Physical Activities Randomized Controlled Trial in Mild/Moderate Depression Participants: SONRIE Project,NA,,Other,Unknown,Other,COMPLETED,University of Cadiz,2019-09-01,2020-02-28,Long-term,0.05,,3,0.07471722255609645,1
NCT03702036,Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma,,molibresib,CAR-T,Unknown,Other,NO_LONGER_AVAILABLE,GlaxoSmithKline,,,Unknown,0.1,,2,0.07698823195888042,1
NCT04230564,Acute Myeloid Leukemia Real World Treatment Patterns,,"azacitidine, venetoclax, glasdegib",Other,Unknown,Leukemia,WITHDRAWN,Pfizer,2020-10-31,2021-03-31,Long-term,0.1,,3,0.07471722255609645,1
NCT05006664,Brentuximab Vedotin in Combination With CHEP in Patient With PTCL,PHASE2,"Adcetris 50 MG Injection, Endoxan, Doxorubicin, Etoposide, Prednisone tablet",ADC,Unknown,Lymphoma,UNKNOWN,Czech Lymphoma Study Group,2021-10,2024-10,Long-term,0.3,2.0,0,0.3000000000000005,3
NCT05734898,NKG2D CAR-NK & r/rAML,NA,,Other,Unknown,Other,UNKNOWN,Zhejiang University,2023-03,2024-04,Long-term,0.05,,3,0.07471722255609645,1
NCT07371663,An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors,"PHASE1, PHASE2","TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg",Other,Unknown,Solid Tumor,RECRUITING,"Beijing Tide Pharmaceutical Co., Ltd",2025-12-03,2028-09-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06697275,Evaluation of the Efficacy of a Virtual Reality When Placing a Needle on an Implantable Venous Access Device in Children With Leukemia,NA,,Other,Unknown,Leukemia,RECRUITING,"University Hospital, Clermont-Ferrand",2024-11-15,2027-10-01,Long-term,0.05,,3,0.07471722255609645,1
NCT01832857,"Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients",PHASE2,CPI-613,Other,Unknown,Solid Tumor,TERMINATED,Cornerstone Pharmaceuticals,2013-06,2016-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04862767,TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor,PHASE1,TASO-001((TGF-β2 targeting anti-sense oligonucleotide),Other,Unknown,Solid Tumor,COMPLETED,Autotelicbio,2021-03-09,2023-08-21,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03881592,Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness,,,Other,Unknown,Leukemia,UNKNOWN,Brno University Hospital,2018-11-01,2019-06,Long-term,0.1,,3,0.07471722255609645,1
NCT03939234,Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.,PHASE2,,Other,PD-L1,Leukemia,COMPLETED,Lars Møller Pedersen,2019-04-26,2021-03-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04789434,PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT,PHASE3,PD-1 Inhibitor Tislelizumab maintenance therapy,Other,PD-1,Lymphoma,UNKNOWN,Ruijin Hospital,2021-07-09,2023-07-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT05877664,Study of ZG0895.HCl in Patients With Advanced Solid Tumors,PHASE1,ZG0895 Hydrochloride for Injection,Other,Unknown,Solid Tumor,RECRUITING,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",2023-08-08,2026-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03754764,A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy,"PHASE1, PHASE2",,CAR-T,CD19,Leukemia,UNKNOWN,Chinese PLA General Hospital,2018-11-23,2022-11-23,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT07213609,A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors,"PHASE1, PHASE2",GSK5460025,Other,Unknown,Solid Tumor,RECRUITING,GlaxoSmithKline,2025-10-20,2028-09-28,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00906698,Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2,PHASE1,"BIBW 2992 low (20mg) dosage, BIBW 2992 medium (40mg) dosage, BIBW 2992 high (50mg) dosage, Vinorelbine per os 60 mg/m², Vinorelbine per os 80 mg/m², Vinorelbine i.v. 25 mg/m²",Other,"HER2, EGFR",Other,COMPLETED,Boehringer Ingelheim,2009-06,2013-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00039377,"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",PHASE2,"imatinib mesylate, methotrexate, vincristine sulfate, leucovorin calcium, tacrolimus, etoposide, cyclophosphamide, cytarabine",Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2002-04,2012-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04405375,GPED Regimen for Relapsed/Refractory or Advanced ENKTCL,PHASE2,"gemcitabin, Pegaspargase, Etoposide, Dexamethasone",Other,Unknown,Lymphoma,UNKNOWN,Beijing Tongren Hospital,2020-03-21,2023-04-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01327612,Open Label Extension Study of Conatumumab and Ganitumab (AMG 479),PHASE2,Modified FOLFOX6,CAR-T,Unknown,Lymphoma,COMPLETED,Amgen,2011-03-03,2020-02-05,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT04074330,A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma,"PHASE1, PHASE2","TAK-981, Rituximab",Other,CD20,Lymphoma,TERMINATED,Takeda,2019-10-15,2023-04-26,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02583165,A Study in Adult Subjects With Select Advanced Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,MedImmune LLC,2015-11-09,2018-12-19,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00493467,Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas,PHASE2,"Ibritumomab Tiuxetan (Zevalin), Rituximab",Other,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2006-06,2015-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01149707,"Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis",PHASE2,"PUR 0110 Rectal Enema 250 mg, PUR 0110 Rectal Enema 500 mg, PUR 0110 Rectal Enema 1000 mg, Placebo Enema",Other,Unknown,Other,COMPLETED,PurGenesis Technologies Inc.,2010-06-01,2014-10-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03552692,Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma,PHASE2,Venetoclax,Other,Unknown,Lymphoma,TERMINATED,Fondazione Italiana Linfomi - ETS,2018-09-25,2020-03-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03080311,A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,PHASE1,APG-1252,Other,Unknown,Solid Tumor,COMPLETED,Ascentage Pharma Group Inc.,2017-02-12,2020-06-22,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06453044,Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma,PHASE2,Polatuzumab Vedotin,Other,Unknown,Lymphoma,RECRUITING,City of Hope Medical Center,2024-09-09,2028-03-14,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00004009,R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia,PHASE1,tipifarnib,Other,Unknown,Leukemia,COMPLETED,"University of Maryland, Baltimore",1999-06,2001-04,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05806099,"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","PHASE1, PHASE2",MBS303,Other,Unknown,Lymphoma,RECRUITING,"Beijing Mabworks Biotech Co., Ltd.",2023-06-28,2025-11,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT04571632,Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors,PHASE2,"Avelumab, Ipilimumab 5 MG/ML, Pembrolizumab 100 MG in 4 ML Injection",Other,Unknown,Solid Tumor,UNKNOWN,Universitair Ziekenhuis Brussel,2020-09-22,2023-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05830045,A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors,PHASE1,QLP2117,Other,Unknown,Solid Tumor,RECRUITING,"Qilu Pharmaceutical Co., Ltd.",2023-05-19,2025-04-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03744819,Biomarkers for Prediction of Tumor Response to Radiotherapy,,,Other,Unknown,Solid Tumor,RECRUITING,Chuangzhen Chen,2018-10-29,2025-11-30,Long-term,0.1,,3,0.07471722255609645,1
NCT01028430,B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging,,,Other,Unknown,Leukemia,COMPLETED,Northwell Health,1998-07,2023-09,Long-term,0.1,,3,0.07471722255609645,1
NCT00278330,Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia,PHASE1,"alvocidib, vorinostat",Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2006-01,2009-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05659628,CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL,PHASE1,,CAR-T,CD19,Lymphoma,RECRUITING,Ningbo No. 1 Hospital,2022-12,2024-12,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00251407,"Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies",PHASE1,"Taxotere, Cisplatin, CPT-11",Other,Unknown,Solid Tumor,COMPLETED,Dana-Farber Cancer Institute,1999-09,2003-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05146336,CytOSorb TreatMent Of Critically Ill PatientS Registry,,,CAR-T,Unknown,Other,RECRUITING,"CytoSorbents, Inc",2022-06-22,2032-06,Long-term,0.1,,2,0.07698823195888042,1
NCT05338892,Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,,,Other,Unknown,Lymphoma,COMPLETED,Regeneron Pharmaceuticals,2022-06-22,2023-10-05,Long-term,0.1,,3,0.07471722255609645,1
NCT01915992,"Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies",NA,,Other,Unknown,Leukemia,UNKNOWN,Assistance Publique Hopitaux De Marseille,2013-02,2014-08,Long-term,0.05,,3,0.07471722255609645,1
NCT02343536,"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",PHASE1,"Oral Azacitidine, Rituximab, cyclophosphamide, Vincristine, Prednisone",Other,Unknown,Lymphoma,COMPLETED,Celgene,2015-04-29,2020-01-29,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00098436,Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias,PHASE1,"laromustine, temozolomide",Other,Unknown,Leukemia,COMPLETED,Vion Pharmaceuticals,2004-09,2006-10,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06814444,Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia,,,Other,Unknown,Leukemia,RECRUITING,IRCCS Azienda Ospedaliero-Universitaria di Bologna,2023-11-11,2029-12-11,Long-term,0.1,,3,0.07471722255609645,1
NCT06559644,Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia,EARLY_PHASE1,,Other,Unknown,Leukemia,NOT_YET_RECRUITING,The First Affiliated Hospital of Soochow University,2024-09-01,2026-09-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00428909,"Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)",PHASE1,Imatinib/Acetaminophen,Other,Unknown,Leukemia,COMPLETED,Novartis Pharmaceuticals,2006-11,2008-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04493099,Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML,"PHASE1, PHASE2","Alvocidib Hydrochloride, Decitabine, Venetoclax",Other,Unknown,Leukemia,WITHDRAWN,M.D. Anderson Cancer Center,2020-10,2020-10-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT01711398,"Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors","PHASE1, PHASE2",Drug,Other,Unknown,Solid Tumor,COMPLETED,Elro Pharma,2012-07,2014-09,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02082977,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",PHASE1,GSK2816126,Other,Unknown,Lymphoma,TERMINATED,GlaxoSmithKline,2014-04-24,2017-06-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04396119,Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study,,,Other,Unknown,Lymphoma,COMPLETED,The Christie NHS Foundation Trust,2020-02-11,2020-04-13,Long-term,0.1,,3,0.07471722255609645,1
NCT03739619,"Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","PHASE1, PHASE2","Bendamustine, Gemcitabine",Other,Unknown,Lymphoma,COMPLETED,Emory University,2018-11-26,2023-12-22,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02191930,Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma,PHASE2,"B-CAP, Brentuximab Vedotin",Other,Unknown,Lymphoma,COMPLETED,University of Cologne,2015-09,2022-03-16,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00316030,Study of Bexarotene in Patients With Acute Myeloid Leukemia,PHASE1,Bexarotene,Other,Unknown,Leukemia,COMPLETED,Abramson Cancer Center at Penn Medicine,2004-01,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT00936728,White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer,NA,,Other,Unknown,Solid Tumor,COMPLETED,Academic and Community Cancer Research United,2009-07,2017-03-02,Long-term,0.05,,3,0.07471722255609645,1
NCT00578292,"Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO",NA,"Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA",Other,Unknown,Other,TERMINATED,Baylor College of Medicine,2004-02,2016-05,Long-term,0.05,,3,0.07471722255609645,1
NCT03263936,Epigenetic Reprogramming in Relapse/Refractory AML,PHASE1,"Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine",Other,Unknown,Leukemia,COMPLETED,Therapeutic Advances in Childhood Leukemia Consortium,2017-07-11,2020-07-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00005611,BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment,PHASE1,BMS-188797,Other,Unknown,Solid Tumor,UNKNOWN,H. Lee Moffitt Cancer Center and Research Institute,,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT05649371,Multiphasic Prehab Allo-HSCT,NA,,Other,Unknown,Leukemia,UNKNOWN,University of Calgary,2023-01,2024-12,Long-term,0.05,,3,0.07471722255609645,1
NCT01361464,Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia,PHASE2,Tipifarnib,Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2011-05,2014-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04441099,NBE-002 in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",NBE-002,Other,Unknown,Solid Tumor,TERMINATED,NBE-Therapeutics AG,2020-06-19,2023-08-14,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00654732,Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma,PHASE2,"Bleomycin, Dacarbazine, Doxorubicin Hydrochloride, Vinblastine",CAR-T,Unknown,Lymphoma,COMPLETED,M.D. Anderson Cancer Center,2008-03-19,2018-09-05,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT00019032,Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia,PHASE1,,Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),1996-03,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT05765032,Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors,"PHASE1, PHASE2",SHR-A1921；,Other,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",2022-12-30,2025-04-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00052598,Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant,"PHASE1, PHASE2",,Other,Unknown,Leukemia,TERMINATED,Fred Hutchinson Cancer Center,2002-09,2009-11,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00003498,Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma,PHASE2,Antineoplaston therapy (Atengenal + Astugenal),Other,Unknown,Lymphoma,TERMINATED,Burzynski Research Institute,1997-10-13,2007-02-02,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06778863,A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation,PHASE1,CLSP-1025,CAR-T,Unknown,Solid Tumor,RECRUITING,"Clasp Therapeutics, Inc.",2025-02-28,2027-12,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00147121,Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203),"PHASE2, PHASE3","Rituximab + Standard CHOP, Rituximab + Bi-weekly CHOP",Other,Unknown,Lymphoma,COMPLETED,Haruhiko Fukuda,2002-09,2010-02,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT06051695,"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","PHASE1, PHASE2",,CAR-T,Unknown,Solid Tumor,RECRUITING,A2 Biotherapeutics Inc.,2024-04-03,2028-06,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT06045195,Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma,PHASE2,Pembrolizumab,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,University of Cologne,2025-08,2027-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00945828,Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors,NA,,Other,Unknown,Lymphoma,COMPLETED,University of Miami,2003-01,2010-10,Long-term,0.05,,3,0.07471722255609645,1
NCT02370836,Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Cancer Patients,NA,,Other,Unknown,Solid Tumor,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2015-05,2015-09,Long-term,0.05,,3,0.07471722255609645,1
NCT05127811,A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma,PHASE1,ZN-d5,Other,Unknown,Lymphoma,TERMINATED,Zentera Therapeutics HK Limited,2021-10-21,2023-05-26,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT01169311,Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure,NA,,Other,Unknown,Other,COMPLETED,Medtronic - MITG,2010-07,2011-03,Long-term,0.05,,3,0.07471722255609645,1
NCT06013111,An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors,PHASE1,,CAR-T,Unknown,Solid Tumor,RECRUITING,"China Medical University, China",2023-10-23,2026-09-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04083911,Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60,PHASE3,"Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF",Other,Unknown,Leukemia,UNKNOWN,The First Affiliated Hospital of Soochow University,2019-04-01,2021-05-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06359509,Study of SYS6020 in BCMA-positive Multiple Myeloma,EARLY_PHASE1,,Other,BCMA,Multiple Myeloma,NOT_YET_RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2024-04,2027-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04645199,National Longitudinal Cohort of Hematological Diseases,,,Other,Unknown,Lymphoma,RECRUITING,"Institute of Hematology & Blood Diseases Hospital, China",2020-12-01,2030-12-01,Long-term,0.1,,3,0.07471722255609645,1
NCT06533332,A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors,PHASE1,ERX-315,Other,Unknown,Solid Tumor,RECRUITING,EtiraRx Australia Pty Ltd,2024-10-14,2025-12-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00613145,Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors,PHASE1,"Capecitabine and Sorafenib, Capecitabine and Sorafenib",Other,Unknown,Solid Tumor,COMPLETED,"SCRI Development Innovations, LLC",2008-02,2009-05,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03728972,"Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type",PHASE2,Pembrolizumab,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,2018-11-09,2025-06-15,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06744075,Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma,NA,,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Centre Henri Becquerel,2024-12-24,2027-12-20,Long-term,0.05,,3,0.07471722255609645,1
NCT04439201,"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)",PHASE2,Palbociclib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),2016-05-31,2021-03-09,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00019019,Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas,PHASE1,"carboxyamidotriazole, paclitaxel",CAR-T,Unknown,Lymphoma,COMPLETED,National Institutes of Health Clinical Center (CC),1994-10,2006-07,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT03384212,CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML,PHASE3,"Cladribine, Fludarabine, Busulfan, Cytarabine",Other,Unknown,Leukemia,UNKNOWN,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",2016-08-01,2022-07-31,Long-term,0.6,3.0,3,0.600000000000001,5
NCT04331119,Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas,PHASE2,Duvelisib,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Washington University School of Medicine,2020-07-23,2026-04-22,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05837767,A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue,NA,,CAR-T,Unknown,Solid Tumor,RECRUITING,Memorial Sloan Kettering Cancer Center,2023-07-24,2026-07-24,Long-term,0.05,,2,0.07698823195888042,1
NCT00116467,Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia,PHASE2,,Other,Unknown,Leukemia,COMPLETED,Cell Genesys,2001-03,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT02072967,Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma,,,Other,Unknown,Lymphoma,COMPLETED,Astellas Pharma Europe B.V.,2012-05,2015-10,Long-term,0.1,,3,0.07471722255609645,1
NCT00930267,Infections in Pediatric Cancer Patients,,,Other,Unknown,Solid Tumor,UNKNOWN,Hadassah Medical Organization,,,Unknown,0.1,,3,0.07471722255609645,1
NCT05858736,"Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",PHASE1,AI-061,CAR-T,Unknown,Solid Tumor,ACTIVE_NOT_RECRUITING,"OncoC4, Inc.",2023-07-11,2025-12-31,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04690192,CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma,"PHASE1, PHASE2","Gemcitabine Injection, busulfan, Melphalan Injection",Other,Unknown,Lymphoma,COMPLETED,"Institute of Hematology & Blood Diseases Hospital, China",2021-01-01,2023-12-30,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00488592,Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers,PHASE2,GM-CSF (Sargramostim),Other,Unknown,Leukemia,COMPLETED,"National Heart, Lung, and Blood Institute (NHLBI)",2007-06,2010-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06782971,Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX,,,Other,Unknown,Leukemia,RECRUITING,Clinical Hub for Interventional Research (CHOIR),2025-06-06,2028-02,Long-term,0.1,,3,0.07471722255609645,1
NCT06375564,Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression,PHASE1,177Lu-AB-3PRGD2 radioligand therapy,Other,Unknown,Solid Tumor,RECRUITING,The First Affiliated Hospital of Xiamen University,2024-06-12,2025-12-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00058799,Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine,PHASE1,,Other,Unknown,Leukemia,COMPLETED,Baylor College of Medicine,1999-06,2010-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00002003,Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas,PHASE2,"Mitoxantrone hydrochloride, Etoposide",Other,Unknown,Lymphoma,COMPLETED,Lederle Laboratories,,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT05808803,Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients,,,Other,Unknown,Leukemia,COMPLETED,Zhongnan Hospital,2016-01-01,2020-10-31,Long-term,0.1,,3,0.07471722255609645,1
NCT00162136,Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.,PHASE1,Ixabepilone,Other,Unknown,Other,COMPLETED,R-Pharm,2005-09,2008-07,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06503107,Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM,"PHASE1, PHASE2",Nanobody-based biepitope BCMA-targeting CAR-T cells,CAR-T,BCMA,Multiple Myeloma,RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2024-04-23,2026-04-18,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02611492,A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults,PHASE3,"Nilotinib, Methotrexate, Aracytine (Ara C), Granulocyte Colony-Stimulating Factor (G-CSF), Depomedrol, Dexamethasone, Vincristine, Imatinib, 6 Mercaptopurine (6MP)",Other,Unknown,Leukemia,UNKNOWN,Assistance Publique - Hôpitaux de Paris,2016-04,2020-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT06550336,A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).,PHASE2,Chidamide,Bispecific,CD30,Lymphoma,ACTIVE_NOT_RECRUITING,The First Hospital of Jilin University,2024-06-30,2027-12-30,Long-term,0.3,2.0,1,0.3000000000000005,3
NCT04079309,Anxiolytic Effects of Lavender and Orange Oil,NA,,Other,Unknown,Other,COMPLETED,Ankara University,2019-08-01,2019-12-20,Long-term,0.05,,3,0.07471722255609645,1
NCT00705809,T-Cell Project: Epidemiologic Component,,,Other,Unknown,Lymphoma,COMPLETED,National Cancer Institute (NCI),2008-06-18,,Unknown,0.1,,3,0.07471722255609645,1
NCT02012699,Integrated Cancer Repository for Cancer Research,,,Other,Unknown,Leukemia,RECRUITING,University of Nebraska,2013-11-01,2099-12,Long-term,0.1,,3,0.07471722255609645,1
NCT02552121,Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors,"PHASE1, PHASE2",Tisotumab vedotin (HuMax-TF-ADC),ADC,Unknown,Solid Tumor,COMPLETED,Seagen Inc.,2015-11-30,2017-12-13,Long-term,0.3,1.0,0,0.17008722943722948,3
NCT05094206,"CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies",PHASE1,,CAR-T,Unknown,Lymphoma,TERMINATED,Medical College of Wisconsin,2022-06-30,2024-01-29,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00195533,Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients,,"piperacillin-tazobactam, glycopeptide",Other,Unknown,Lymphoma,COMPLETED,Wyeth is now a wholly owned subsidiary of Pfizer,2001-07,2005-03,Long-term,0.1,,3,0.07471722255609645,1
NCT03913949,"A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies",PHASE1,APG-2575,Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,Ascentage Pharma Group Inc.,2019-06-03,2024-10-20,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06532552,"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia",PHASE2,"VACl, VACh, VACl Alternating With VACh, VA",Other,Unknown,Leukemia,RECRUITING,The First Affiliated Hospital of Soochow University,2024-07-29,2027-08-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05564052,A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma,PHASE2,"Ibrutinib, Lenalidomide, Rituximab, Bortezomib",Other,Unknown,Lymphoma,COMPLETED,"Janssen Research & Development, LLC",2022-12-06,2023-12-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04550949,To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors,PHASE3,"QL1206, Xgeva",Other,Unknown,Solid Tumor,UNKNOWN,"Qilu Pharmaceutical Co., Ltd.",2019-04-26,2021-03-01,Long-term,0.6,3.0,3,0.600000000000001,5
NCT03661307,"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","PHASE1, PHASE2","Decitabine, Quizartinib, Venetoclax",Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2018-10-31,2028-01-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00339144,Study of Dasatinib (BMS-354825) in Patients With Solid Tumors,PHASE1,"Dasatinib, Dasatinib, Dasatinib",Other,Unknown,Solid Tumor,COMPLETED,Bristol-Myers Squibb,2007-01,2008-09,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00008164,Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia,PHASE2,,Other,Unknown,Lymphoma,UNKNOWN,Herbert Irving Comprehensive Cancer Center,1997-01,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT00216164,Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,PHASE2,"Rituximab, Gemcitabine",Other,Unknown,Lymphoma,TERMINATED,Hoosier Cancer Research Network,2005-04,2007-03,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05276609,ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors,PHASE1,"HS-20093 (Phase Ia: Dose escalation), HS-20093 (Phase Ib: Dose expansion)",Other,Unknown,Solid Tumor,UNKNOWN,"Shanghai Hansoh Biomedical Co., Ltd",2021-11-28,2023-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05449899,G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT,"PHASE2, PHASE3","Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU), Fludarabine (FLU), Cyclophosphamide (CY)",Other,Unknown,Leukemia,UNKNOWN,"Nanfang Hospital, Southern Medical University",2022-07,2023-12,Long-term,0.6,2.0,3,0.3133375460709372,5
NCT00327132,Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome,NA,"Omeprazole, Amoxicillin, Clarithromycin",Other,Unknown,Lymphoma,COMPLETED,"National Health Research Institutes, Taiwan",2006-07,2015-12,Long-term,0.05,,3,0.07471722255609645,1
NCT00905398,Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,"PHASE1, PHASE2",Nilotinib,Other,Unknown,Lymphoma,TERMINATED,Rony Schaffel,2009-05,2012-06,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT02070393,Breast-Sparing Proton Therapy for Hodgkin's Disease,EARLY_PHASE1,,Other,Unknown,Other,TERMINATED,Indiana University,2011-09,2015-02,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04334993,Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study,PHASE2,Blinatumomab,Other,Unknown,Solid Tumor,UNKNOWN,Israeli Medical Association,2021-01-01,2023-05-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT04645706,Innate T Cells and TKI Discontinuation,,,Other,Unknown,Leukemia,ACTIVE_NOT_RECRUITING,Poitiers University Hospital,2021-04-20,2028-04,Long-term,0.1,,3,0.07471722255609645,1
NCT01449058,A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,PHASE1,"BYL719, MEK162",Other,Unknown,Solid Tumor,COMPLETED,Array BioPharma,2012-03,2016-08-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02992834,Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma,PHASE4,,Other,CD19,Lymphoma,UNKNOWN,jiangjingting,2016-12,2020-08,Long-term,0.05,4.0,3,0.04999999999999991,1
NCT04895709,A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors,"PHASE1, PHASE2","BMS-986340, BMS-936558-01, Docetaxel",CAR-T,Unknown,Solid Tumor,RECRUITING,Bristol-Myers Squibb,2021-05-27,2028-07-07,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04825899,Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma,,,Other,Unknown,Lymphoma,UNKNOWN,Fudan University,2021-03-08,2022-02-08,Long-term,0.1,,3,0.07471722255609645,1
NCT07114432,RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma,PHASE1,BCMA/CD19-targeted allogeneic CAR-T,CAR-T,"CD19, BCMA",Multiple Myeloma,NOT_YET_RECRUITING,Tianjin Medical University Cancer Institute and Hospital,2025-08,2027-12,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT02667093,Samples From Leukemia Patients and Their Donors to Identify Specific Antigens,,,Other,Unknown,Leukemia,UNKNOWN,"PersImmune, Inc",2013-01,2020-12,Long-term,0.1,,3,0.07471722255609645,1
NCT00064584,Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML),PHASE1,CT53518,Other,Unknown,Leukemia,COMPLETED,"Millennium Pharmaceuticals, Inc.",2002-05,2005-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05950204,"Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia.",NA,,Other,Unknown,Leukemia,UNKNOWN,"Coordinación de Investigación en Salud, Mexico",2022-09-10,2024-12-31,Long-term,0.05,,3,0.07471722255609645,1
NCT03052933,Copanlisib and Gemcitabine in Relapsed/Refractory PTCL,"PHASE1, PHASE2","Copanlisib, Gemcitabine",Other,Unknown,Other,COMPLETED,Chonnam National University Hospital,2018-02-01,2021-07-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06323447,Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia,,,Other,Unknown,Lymphoma,NOT_YET_RECRUITING,"Leuko Labs, Inc.",2025-04-01,2026-03-30,Long-term,0.1,,3,0.07471722255609645,1
NCT04195347,Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase,"PHASE1, PHASE2",CM4620,Other,Unknown,Other,RECRUITING,St. Jude Children's Research Hospital,2020-09-04,2027-01,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT00666211,Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain,PHASE3,,CAR-T,Unknown,Lymphoma,COMPLETED,Vanderbilt-Ingram Cancer Center,2005-05,2010-01,Long-term,0.6,3.0,2,0.600000000000001,5
NCT06277011,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research,EARLY_PHASE1,Metabolically Armed CD19 CAR-T cells,CAR-T,CD19,Lymphoma,RECRUITING,Anhui Provincial Hospital,2023-02-10,2025-02-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00378534,Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants,PHASE2,"Fludarabine, Cyclosporine, Cyclophosphamide",Other,Unknown,Leukemia,COMPLETED,"National Heart, Lung, and Blood Institute (NHLBI)",2006-09,2014-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00114764,Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML),PHASE2,"filgrastim, pegfilgrastim",Other,Unknown,Leukemia,COMPLETED,Amgen,2003-03,2004-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02301364,Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),PHASE2,Buparlisib (BKM120),Other,Unknown,Lymphoma,COMPLETED,Memorial Sloan Kettering Cancer Center,2014-11-20,2016-10-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07098364,ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma,"PHASE1, PHASE2",,CAR-T,CD19,Lymphoma,RECRUITING,Fred Hutchinson Cancer Center,2025-12-27,2030-10-04,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04493164,CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome,PHASE2,"Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine",Other,Unknown,Leukemia,RECRUITING,M.D. Anderson Cancer Center,2020-12-30,2026-06-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01843998,Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),PHASE2,Sirolimus 0.1% Ointment,Other,Unknown,Lymphoma,WITHDRAWN,Stefan Schieke MD,2014-02,2015-05,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01742793,"An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)",PHASE1,lenalidomide (Revlimid) and romidepsin (Istodax),Other,Unknown,Lymphoma,TERMINATED,Yale University,2012-10,2016-08,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04663516,Effectiveness of Exercise Through Video Games in Reducing Fatigue Among Children With Leukemia,NA,,Other,Unknown,Leukemia,COMPLETED,King Saud University,2019-09-01,2020-12-31,Long-term,0.05,,3,0.07471722255609645,1
NCT03366116,5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors,PHASE1,aza-TdC,Other,Unknown,Solid Tumor,RECRUITING,National Cancer Institute (NCI),2018-11-05,2026-09-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06940804,A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm,PHASE2,,Other,Unknown,Solid Tumor,WITHDRAWN,BioNTech SE,2025-07,2042-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06371716,Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions,NA,,Other,Unknown,Solid Tumor,TERMINATED,IRCCS San Raffaele,2019-09-12,2020-06-12,Long-term,0.05,,3,0.07471722255609645,1
NCT01769911,Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma,NA,"carmustine, cytarabine, melphalan, etoposide, O6-benzylguanine",CAR-T,Unknown,Lymphoma,WITHDRAWN,Fred Hutchinson Cancer Center,2015-02,2019-02,Long-term,0.05,,2,0.07698823195888042,1
NCT04694911,Development of the Oncology Opportunity Cost Assessment Tool,,,Other,Unknown,Other,COMPLETED,Thomas Jefferson University,2019-11-21,2021-05-11,Long-term,0.1,,3,0.07471722255609645,1
NCT05224271,"Evaluating Patient Reported Outcomes in Radiation Therapy, the PRO-RT Study",,,CAR-T,Unknown,Other,COMPLETED,Mayo Clinic,2022-03-02,2023-04-10,Long-term,0.1,,2,0.07698823195888042,1
NCT00129571,Study of XL820 in Adults With Solid Tumors,PHASE1,XL820,Other,Unknown,Solid Tumor,COMPLETED,Exelixis,2005-08,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT03729609,"Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion ""Untreated CD30-Positive Hodgkin's Lymphoma""",,Brentuximab vedotin (Genetical Recombination),Bispecific,CD30,Lymphoma,COMPLETED,Takeda,2018-11-01,2023-09-27,Long-term,0.1,,1,0.09171632886378081,1
NCT00022932,Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP,PHASE2,Iodine-131 Anti-B1 Antibody,Other,Unknown,Lymphoma,UNKNOWN,Corixa Corporation,2000-01,,Unknown,0.3,2.0,3,0.3133375460709372,3
NCT00422032,2 Arm Study of Clofarabine IV in MDS Patients,PHASE2,Clofarabine,Other,Unknown,Leukemia,COMPLETED,M.D. Anderson Cancer Center,2006-01,2011-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05779332,"Prevalence, Etiology and Effects on Oral Health and Life Quality of Molar Incisor Hypomineralization",,,CAR-T,Unknown,Other,COMPLETED,Recep Tayyip Erdogan University Training and Research Hospital,2020-02-01,2020-04-30,Long-term,0.1,,2,0.07698823195888042,1
NCT01447732,Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors,PHASE1,CEP-37250/KHK2804,CAR-T,Unknown,Solid Tumor,COMPLETED,"Kyowa Kirin Co., Ltd.",2011-10,2015-01,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT00863187,Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab,NA,,Other,Unknown,Lymphoma,UNKNOWN,Rambam Health Care Campus,2009-02,2010-02,Long-term,0.05,,3,0.07471722255609645,1
NCT03447314,Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,PHASE1,"GSK1795091, GSK3174998, GSK3359609, Pembrolizumab",Other,Unknown,Solid Tumor,COMPLETED,GlaxoSmithKline,2018-03-26,2020-07-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02665416,"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors",PHASE1,"Selicrelumab, Vanucizumab, Bevacizumab",Other,Unknown,Solid Tumor,COMPLETED,Hoffmann-La Roche,2016-01-25,2019-10-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT06376292,"A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis",PHASE2,Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases,Other,Unknown,Solid Tumor,RECRUITING,"Second Affiliated Hospital, School of Medicine, Zhejiang University",2024-01-06,2026-01-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02883036,Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia,,,Other,Unknown,Leukemia,UNKNOWN,"Nanfang Hospital, Southern Medical University",2016-09,2021-09,Long-term,0.1,,3,0.07471722255609645,1
NCT03232307,Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma,PHASE2,"Dexamethasone, Ibrutinib, Lenalidomide",Other,CD20,Lymphoma,WITHDRAWN,M.D. Anderson Cancer Center,2019-07-01,2021-07-01,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT07121036,High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors,PHASE1,high - dose vitamin C,Other,Unknown,Solid Tumor,RECRUITING,Zhongnan Hospital,2025-03-30,2026-12-31,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04050709,QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers,PHASE1,,Other,PD-L1,Solid Tumor,ACTIVE_NOT_RECRUITING,"ImmunityBio, Inc.",2019-07-18,2025-11-30,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03730363,Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma,PHASE1,Pentamidine,Other,Unknown,Lymphoma,COMPLETED,Reinhold Munker,2018-12-19,2019-05-23,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00571493,"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","PHASE1, PHASE2","Bortezomib, BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)",CAR-T,Unknown,Lymphoma,COMPLETED,University of Nebraska,2006-04-14,2014-11-01,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT04253314,A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation,,,Other,Unknown,Leukemia,COMPLETED,AbbVie,2020-03-13,2023-02-16,Long-term,0.1,,3,0.07471722255609645,1
NCT02564484,iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy,,,Other,Unknown,Lymphoma,COMPLETED,St. Jude Children's Research Hospital,2016-02-08,2021-05-12,Long-term,0.1,,3,0.07471722255609645,1
NCT05225584,"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors",PHASE1,KT-333,Other,Unknown,Lymphoma,COMPLETED,"Kymera Therapeutics, Inc.",2022-05-19,2025-03-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT03493906,Patient Ambassador Support in Newly Diagnosed Patients With Acute Leukemia During Treatment,NA,,Other,Unknown,Leukemia,COMPLETED,"Rigshospitalet, Denmark",2018-03-01,2019-09-01,Long-term,0.05,,3,0.07471722255609645,1
NCT01836484,"Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma",,,CAR-T,Unknown,Solid Tumor,COMPLETED,Barts & The London NHS Trust,2012-06,2018-12,Long-term,0.1,,2,0.07698823195888042,1
NCT00897936,DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia,,,Other,Unknown,Leukemia,COMPLETED,ECOG-ACRIN Cancer Research Group,2006-03-23,2009-10-15,Long-term,0.1,,3,0.07471722255609645,1
NCT01620736,Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,PHASE2,Raltegravir,Other,Unknown,Leukemia,WITHDRAWN,Washington University School of Medicine,2012-01,2013-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01933711,Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma,PHASE3,rituximab,Other,CD20,Lymphoma,UNKNOWN,University Hospital Heidelberg,2002-07,2016-12,Long-term,0.6,3.0,3,0.600000000000001,5
NCT00201734,"Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary","PHASE1, PHASE2","Capecitabine, Carboplatin, Paclitaxel",CAR-T,Unknown,Solid Tumor,TERMINATED,Ohio State University Comprehensive Cancer Center,2005-06,2007-11,Long-term,0.3,1.0,2,0.1626669915300076,3
NCT02626234,A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,PHASE1,"INC280, digoxin, rosuvastatin",Other,Unknown,Solid Tumor,COMPLETED,Novartis Pharmaceuticals,2015-12-08,2017-02-28,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT05807932,"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","PHASE1, PHASE2","Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil",Other,Unknown,Leukemia,RECRUITING,"Heinrich-Heine University, Duesseldorf",2023-06-26,2026-01-31,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT03386721,Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors,PHASE2,"simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine, Vinorelbine",Other,PD-L1,Solid Tumor,TERMINATED,Hoffmann-La Roche,2018-02-19,2021-12-30,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00039416,Imatinib Mesylate in Treating Patients With Myelofibrosis,PHASE2,imatinib mesylate,Other,Unknown,Leukemia,COMPLETED,National Cancer Institute (NCI),2002-04,2007-08,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00766116,Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML),"PHASE1, PHASE2","5-Azacitidine, Gemtuzumab ozogamicin",Other,Unknown,Leukemia,COMPLETED,"University of California, San Diego",2005-07,2014-09-26,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT07018752,A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas,"PHASE1, PHASE2","roginolisib, golcadomide, azacitidine",Other,Unknown,Lymphoma,RECRUITING,The Lymphoma Academic Research Organisation,2025-08-20,2028-04,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06293898,Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors,PHASE1,BL-M07D1,CAR-T,HER2,Solid Tumor,RECRUITING,SystImmune Inc.,2024-02-09,2028-12-15,Long-term,0.1,1.0,2,0.1626669915300076,1
NCT04910698,Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia,,Antibiotic,Other,Unknown,Leukemia,COMPLETED,Poitiers University Hospital,2020-01-01,2020-06-01,Long-term,0.1,,3,0.07471722255609645,1
NCT00918463,A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),PHASE2,dasatinib,Other,Unknown,Lymphoma,TERMINATED,Weill Medical College of Cornell University,2009-06,2010-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT02777021,Home Away From Home - Quality of Life Surveys,,,Other,Unknown,Leukemia,COMPLETED,Children's Hospital of Philadelphia,2016-09,2019-07-18,Long-term,0.1,,3,0.07471722255609645,1
NCT00008021,"Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma",PHASE1,"cyclosporine, paclitaxel",Other,Unknown,Lymphoma,UNKNOWN,"University of California, Davis",2001-02,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT01657214,"Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients",PHASE1,SAR125844,Other,Unknown,Solid Tumor,COMPLETED,Sanofi,2012-09,2016-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT07328516,Natural History Study of Early Life Exposures in Agriculture (ELEA),,,Other,Unknown,Leukemia,ENROLLING_BY_INVITATION,National Cancer Institute (NCI),2026-02-09,2027-12-23,Long-term,0.1,,3,0.07471722255609645,1
NCT01283516,A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase,PHASE1,LDK378,Other,Unknown,Lymphoma,COMPLETED,Novartis Pharmaceuticals,2011-01-24,2016-05-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,PHASE3,"cyclophosphamide, doxorubicin, prednisone, vincristine",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,SWOG Cancer Research Network,2001-03,2011-09,Long-term,0.6,3.0,3,0.600000000000001,5
NCT01892852,Acupuncture for Chemotherapy-induced Peripheral Neuropathy,NA,,Other,Unknown,Lymphoma,UNKNOWN,Pusan National University Hospital,2013-06,2014-04,Long-term,0.05,,3,0.07471722255609645,1
NCT02450149,"Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors",NA,sorafenib,Other,Unknown,Solid Tumor,COMPLETED,Samsung Medical Center,2016-05-30,2016-08,Long-term,0.05,,3,0.07471722255609645,1
NCT00596336,Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients,PHASE2,"Imiquimod cream, influenza vaccine",Other,Unknown,Leukemia,TERMINATED,The Royal Bournemouth Hospital,2007-10,2011-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT03674411,Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy,PHASE2,"Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion",Other,Unknown,Lymphoma,ACTIVE_NOT_RECRUITING,"Masonic Cancer Center, University of Minnesota",2019-01-02,2020-06-23,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT00860171,Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,PHASE1,,Other,Unknown,Lymphoma,TERMINATED,Fred Hutchinson Cancer Center,2009-02,2015-03,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT04183764,MAX-40279-01 in Patients With Advanced Solid Tumors,PHASE1,MAX-40279-01,Other,Unknown,Solid Tumor,UNKNOWN,"Maxinovel Pty., Ltd.",2019-11-28,2022-11-01,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00462332,Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia,PHASE2,"Fludarabine, Campath, Campath, Fludarabine, Campath, Campath",Other,Unknown,Leukemia,COMPLETED,Gruppo Italiano Malattie EMatologiche dell'Adulto,2007-05,2011-06,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01568632,Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma,PHASE1,Imetelstat,Other,Unknown,Lymphoma,WITHDRAWN,National Cancer Institute (NCI),2012-03,,Unknown,0.1,1.0,3,0.15123598159865156,1
NCT00005998,Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease,PHASE2,"carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, retrovirus vector LN",CAR-T,Unknown,Lymphoma,WITHDRAWN,"Masonic Cancer Center, University of Minnesota",2000-01,2003-03,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT04895436,Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL),PHASE2,"Venetoclax, Obinutuzumab",Other,Unknown,Leukemia,RECRUITING,AbbVie,2022-03-28,2026-11,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT06928909,Leukemia Adapted Protocol,,,Other,Unknown,Leukemia,RECRUITING,Baylor College of Medicine,2025-01-01,2028-12-31,Long-term,0.1,,3,0.07471722255609645,1
NCT06697899,TGRX-678 Phase I Oral Pharmacokinetic Study,PHASE1,TGRX-678,Other,Unknown,Leukemia,COMPLETED,"Shenzhen TargetRx, Inc.",2024-11-24,2025-01-06,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00995332,"Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine","PHASE1, PHASE2","Cytarabine, all-trans retinoic acid, valproic acid",Other,Unknown,Leukemia,COMPLETED,University of Bergen,2009-09,2013-02,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT07248163,Universal CAR-T Cell Therapy for NHL,NA,BRL-301,CAR-T,Unknown,Lymphoma,RECRUITING,Bioray Laboratories,2025-03-11,2027-08-15,Long-term,0.05,,2,0.07698823195888042,1
NCT04296786,Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study,PHASE2,"Sintilimab, Chidamide",Other,Unknown,Lymphoma,UNKNOWN,Peking Union Medical College Hospital,2019-11-01,2022-12,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT01500161,Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match,PHASE2,"Busulfan, Clofarabine, Fludarabine, Melphalan, Carmustine, Etoposide, Cytarabine",CAR-T,Unknown,Lymphoma,TERMINATED,Texas Oncology Cancer Center,2011-11,2013-11,Long-term,0.3,2.0,2,0.3111600000396263,3
NCT04321161,Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment,EARLY_PHASE1,Bicanorm,Other,Unknown,Leukemia,COMPLETED,University of Freiburg,2020-02-25,2020-03-18,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT00250042,A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec,PHASE2,Gleevec and Arsenic Trioxide,Other,Unknown,Leukemia,COMPLETED,New Mexico Cancer Research Alliance,2004-04,2005-04,Long-term,0.3,2.0,3,0.3133375460709372,3
NCT05764486,A Study About the Operation Efficacy and the Early Stage Safety of Heavy Ion Beam Treatment System in Solid Tumor,NA,,Other,Unknown,Solid Tumor,COMPLETED,"Taipei Veterans General Hospital, Taiwan",2022-06-21,2022-12-20,Long-term,0.05,,3,0.07471722255609645,1
NCT02912754,Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,"PHASE1, PHASE2","ruxolitinib, ibrutinib",Other,Unknown,Leukemia,UNKNOWN,Sunnybrook Health Sciences Centre,2017-03,2018-12,Long-term,0.3,1.0,3,0.15123598159865156,3
NCT06415656,VitalTraq for the Detection of CRS,NA,,Other,Unknown,Other,COMPLETED,Duke University,2024-10-13,2025-06-15,Long-term,0.05,,3,0.07471722255609645,1
NCT01119456,A Study of IMC-RON8 in Advanced Solid Tumors,PHASE1,,Other,Unknown,Solid Tumor,COMPLETED,Eli Lilly and Company,2010-05,2013-11,Long-term,0.1,1.0,3,0.15123598159865156,1
NCT02380222,Patient-Reported Outcome Questionnaire for Systemic Mastocytosis,,,Other,Unknown,Leukemia,COMPLETED,Adelphi Values LLC,2014-07,2015-12,Long-term,0.1,,3,0.07471722255609645,1
NCT01226472,Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001,PHASE2,,Other,Unknown,Lymphoma,COMPLETED,"Kyowa Kirin Co., Ltd.",2010-08,2012-09,Long-term,0.3,2.0,3,0.3133375460709372,3
